curriculum vitae jeff a. sloan, ph.d. address office: cancer...

Sloan CV, 5/7/2008

CURRICULUM VITAE Jeff A. Sloan, Ph.D.

ADDRESS

Office: Cancer Center Statistics – Harwick 829 Mayo Clinic Rochester, MN 55905 (507) 284-9985 FAX (507) 266-2477

1. PRESENT ACADEMIC RANK AND POSITION

Professor of Oncology, Mayo Clinic College of Medicine Professor of Health Sciences Research, Mayo Clinic College of Medicine

2. EDUCATION

1991 - Ph.D. (Statistics), University of Manitoba, Dissertation: “Implementation of the Bayesian Paradigm in Multiparameter Distributions,” Supervisor: S. K. Sinha, Ph.D. 1982 - M. Sc. (Statistics), University of Manitoba 1981 - B. Sc. (Honors 1st Class), St. John’s College, Winnipeg

3. BOARD CERTIFICATION(S) 4. MEDICAL LICENSURE 5. HONORS/AWARDS

2005 – Clerkship Directors in Internal Medicine (CDIM) Best Research Poster Award Winner. Medical student well-being: a multicenter study comparing quality of life, depression, and burnout in minority and non-minority medical students in the U.S. 2005 – Clerkship Directors in Internal Medicine (CDIM) Best Research Poster Award Winner. A

Multicenter study evaluating the effects of personal well-being on specialty choice among U.S. medical students.

2004 – ISOQOL 2004 – Outstanding QOL article of the year 1998 – SUGI - Best contributed paper for Statistics, Data Analysis, and Modeling section 1998 – AACR - Glaxo-Wellcome best contributed clinical research paper 1997 – Academy of Psychosomatic Medicine best poster award 1997 – SUGI - Best contributed paper for Statistics, Data Analysis, and Modeling section

1

Sloan CV, 5/7/2008

1995 – Canadian Diabetes Association Novo Nordisk manuscript of the year award 1995-1996 – Manitoba Nursing Research Award for best research project 1985-1988 – University of Manitoba Graduate Fellowship 1981 – First Class Designation for Honor’s degree 1978 – Malcolm Scholarship for French 1977 – Entrance Scholarship, St. John’s College

6. MILITARY SERVICE 7. PREVIOUS PROFESSIONAL POSITIONS AND MAJOR APPOINTMENTS

May 1982 - Sept. 1983 Research Analyst, Saskatchewan Housing Corporation, Regina

Sept. 1982 - Sept. 1983 Sessional Lecturer in Statistics, Department of Mathematics, University of Regina

Sept. 1983 - June 1984 Management Consultant for the Saskatchewan Computing Facility, (SASKCOMP) regarding statistical analysis of mainframe systems

Sept. 1983 - June 1984 Special Lecturer/Assistant Professor in Statistics, Department of Mathematics, University of Regina

Sept. 1984 - June 1987 Sessional Lecturer in Statistics, Department of Statistics, University of Manitoba

July 1984 - Jan. 1986 Statistical Consultant, Statistical Advisory Service, University of Manitoba

June 1981 - Maintain a professional practice for statistical consultation under the name Significant Findings

Sept. 1991 - July 1995 Statistical Consultant, Clinical Nursing Research Program, St. Boniface General Hospital Research Center

Sept. 1991 - May 1992 Assistant Professor in Statistics, University of Winnipeg

Feb. 1986 - July 1995 Statistical Consultant, Manitoba Nursing Research Institute

May 1992 - July 1995 Associate Professor, Faculty of Nursing, University of Manitoba

March 1994 - Clinical Research Associate, Health Sciences Centre, Winnipeg

July 1995 - Adjunct Professor, faculty of Nursing, University of Manitoba

Sept. 1995 – March 1998 Research Associate, Department of Health Sciences Research, Mayo Clinic, Rochester, MN

March 1998 – 2003 Senior Associate Consultant, Department of Health Sciences Research, Mayo Clinic, Rochester, MN

August 1999 – 2008 Iowa State University Graduate Faculty Membership Appointment (Adjunct Professor)

March 2003 – present Consultant, Department of Health Sciences Research, Mayo Clinic

2

Sloan CV, 5/7/2008

Rochester, MN

Pending Oct. 2004 Professor, Department of Health Sciences Research, Mayo Clinic Rochester, MN

Summary: more than fifteen years of experience as an independent statistical consultant involving over 500 individual research projects. More than a decade of experience teaching Statistics at the university level

8. PROFESSIONAL MEMBERSHIPS AND SOCIETIES (Extramural Only)

a. Membership in Professional Organizations

2005 – present, GOG QOL Committee 2004 – GI Scientific Leadership Council, Coalition of National Cancer Cooperative Groups. 2003 – American Psychosocial Oncology Society 2001 – present, MCC Protocol Review Committee 2000 – present, NCCTG Concept Committee 1997 – Drug Information Association 1996 – International Society for Quality of Life Research 1995 – Society for Clinical Trials 1992 – 1995 Canadian Association of University Schools of Nursing 1990 – Canadian Nursing Research Association 1990 – Biostatistical Society of Canada 1990 – 1996 Canadian Evaluation Society 1988 – 1990 National Computer Graphics Association 1984 – American Statistical Association 1984 – 1996 International Association for Statistical Computing 1983 – Statistical Association of Manitoba 1982 – Statistical Society of Canada

b. Journal Reviewer 2005 – present QOL Section Editor for Journal of Cancer Pain & Symptom Palliation 2003 – present Value in Health

3

Sloan CV, 5/7/2008

2003 – present Health and QOL Outcomes 2003 – present Journal of Obstetrics and Gynecology 2003 – present Cancer Epidemiology Biomarkers and Prevention 2003 – present Medical Care 2003 – present Cancer 2003 – present Journal of Palliative Care 2002 – present Quality of Life Research 2003 – present Journal of Alternative and Complementary Medicine 2003 – present Journal of Cancer Integrative Medicine 2003 – present Journal of International Society of Patients Outcome Research 2002 – present Journal of the National Cancer Institute 2002 – present JAMA 2001– 2002 Journal of Pelvic Surgery 1999 – present Controlled Clinical Trials 1998 – present Canadian Journal of Nursing Research 1996 – present Mayo Clinic Proceedings 1996 – present Journal of Clinical Oncology 1996 – present Statistics in Medicine 1995 – present Neonatal Nursing 1994 – 2001 Statistical Science 1993 – present Canadian Journal of Nursing Research 1988 – 2002 Journal of the IEEE Transactions on Reliability 1989 – 2002 Communications in Statistics

c. Other Professional Activities 2006 – Chair, Mayo/FDA co-sponsored meeting “FDA Guidance on Patient Reported Outcomes: Discussion, Dissemination, and Operationalization”, February 23-25, 2006 in Chantilly, Virginia. 2006 – Co-Chair, ISOQOL Meeting, “Patient Reported Outcomes and FDA Regulatory

4

Sloan CV, 5/7/2008

Guidance Meeting,” June 28-29, 2006 in Washington, DC. 2004 – Served on Planning Committee for NCI International Conference on Malignant Bowel Obstruction: A Model for Randomized Prospective Trials in Palliative Care. 2003 – Chair, Clinsig III Meeting, “Quality of Life III: Translating The Science of QOL Assessment Into Clinical Practice, An Example-Driven Approach for Practicing Clinicians and Clinical Researchers,” October 2-4, 2003 in Scottsdale, AZ. 2003 - present – Served as a reviewer for NCI (Canada) Clinical Trials Group grant renewal. 2002 – Chair, Clinsig II Meeting, “Assessing the Clinical Significance of Quality-of-Life Measures in Oncology Research: State of the Science.” April 5-6, 2002, in Rochester, MN. 2002 - present – Health Outcomes and Quality of Life Assessment 2002 - present – Member, Editorial Board for Health Outcomes and Quality of Life Assessment. 2002 - present – Member, NCI Intergroup Quality of Life Committee 2002 – present – Co-chair Quality of Life Research 9th Annual Conference of the International Society for Quality of Life Research 2002 -present – Chair, Instrument Validity Working Group 2001- present – Member, Cochrane Health-Related Qualify of Life Methods Group 2000 – Chair, Clinsig Meeting, “Consensus Meeting on Assessing Clinical Significance for Quality of Life Measurement in Oncology.” October 6-7, 2000 in Rochester, MN. 2000 - present – Reviewer, NCI CCOP Program Project Review Panel 2000 - present – Member, Society for Clinical Trials Publications Committee 2000-present – Member, Grant Applications Review Committee, SNEM 5 – Statistical Methodology and Quantitative Methodology, Center for Scientific Review, National Institutes of Health, Washington, DC 2000 - present – Member, Grant Applications Review Committee, SNEM 2 – Statistical Methodology and Quantitative Methodology, Center for Scientific Review, National Institutes of Health, Washington, DC 2000 - present – Member Palliative Care Task Force 2000 - present – Leader, NCCTG Quality of Life Working Group 1997 – Session Chair/Organizer, International Society for Quality of Life Research annual meeting “Incorporating quality of life measurement into oncology clinical trials” and “Statistics in quality of life research.” 1997-1998 – External Examiner, Tenure/Promotion Committee - University of Toronto

5

Sloan CV, 5/7/2008

1997– NCCTG representative, Coalition of National Cancer Co-operative Groups 1996-1997 – External Examiner, Tenure Committee - Medical University of South Carolina 1996 – Chair, NCCTG data management task force 1993 – Panel member, expert resource for ASA Section Teaching Statistics in the Health Sciences 1992 – President, Statistical Association of Manitoba 1991-1993 – Sysop, e-mail service of the SSC Biostatistical Society 1991 – Vice President, Statistical Association of Manitoba

9. EDUCATIONAL ACTIVITIES

a. Curriculum/Course Development

b. Teaching Activities 2001, 2002, 2003 Clinical Significance Annual Meetings, CME Course 2000 Guest Lectures in Oncology Core Curriculum Course, August 2. 2000 Issues in Clinical Research Course, December 23 1996, 1997, 1999, 2000 Introductory Statistics, Mayo Clinic 1995 Quantitative Methods for Nursing Research 1993 Introductory Statistics 1991-1992 Introductory Statistics (3 sections), Mathematical Statistics 1988 Introductory Statistics, Bayesian Statistical Methods 1987 Regression/Correlation 1986 Business Statistics 1985 Introductory Statistics 1983-1984 Experimental Design, Statistical Computing, Introductory Statistics (2 sections) 1982-1983 Introductory Statistics 1981 Business Statistics 1980 Introductory Statistics

c. Mentor

6

Sloan CV, 5/7/2008

Thesis Committees (in the role as Committee Member) Anthony Yeung (Ph.D. Statistics), Myrna Rourke (Ph.D., Interdisciplinary), Donna Goodridge (Ph.D., Interdisciplinary), Valerie Wiebe (MN), Anastasia Ngwini (MA), Angels Gines M.D., Ph.D. (Master in Biomedical Sciences in Clinical Research)

Thesis Committees (in the role as a Statistical Consultant)

Angels Gines, M.D., Ph.D., Thesis Defense, Dubai Lecture Hall, Gonda 9-102, August 24, 2005. Thesis Defense: degree of Master in Biomedical Sciences in Clinical Research from Mayo Graduate School. “Impact of Endoscopic Ultrasonography (EUS) and EUS=Fine Needle Aspiration on the Management of Patients with Cancer of the Esophagus.”

Valerie Merle Wiebe, Thesis Oral Defense, Faculty of Nursing, Dafoe Library, August 16, 1999.

Nursing: Doctoral Dissertations

Janet Beaton, Ina Bramadat, Cynthia Cameron, Karen Chalmers, Wanda Chernomas, Annette Gupton, Lorna Guse, Kate Tunna

Nursing: Masters

1996: Lynda Balneaves, Linda Kennedy, Sandy Romano, Corrinne Billinkoff

1995: Terri Ashcroft, Sharon Edmundson, Joan Harbeck, Marilyn Kilpatrick, Ingrid Olson, Sylvia Oosterveen, Verna Pangman, Noelie Lavergne, Kathleen Perron, Michelle Lobchuk, Diana McMillan

1994: David Driedger, Alison Bertram-Farough, Catherine Rippin-Sisler, Barbara Wheeler, Barb Eastveld

1993: Wendy Morgan-Eckley, Barbara Gauthier, Barbara Bilodeau, Susan Goodmanson, Diana McMillan

1992: Katherine Taylor, Sandra Kluka, Maureen Del Pino, Beverly Cann

1991: Carol Schick, Marion Saydak, Jocelyn Reimer-Kent, Judy Kaprowy, Kim Hogg, Joan Schultz, Katherine Hamelin, Shirley Paton, Peri Venkatesh, Carla Shapiro, Katherine Dunn, Mary Driedger, Kathryn Thomson

1990: Elizabeth Thomlinson, Linda Thompson, Susan Stanton, Connie Eccles, Sharon Tschikota, Katie DeLeon-Demare

1989: Debra Vanance, Linda Turner, Marie Knight Kubasiewicz

1988: Loretta Secco, Jean Tkachuk, Bev Wilden, Donna Goodridge, Tina Enns, Cheryl Walker, Diana Barkwell

1987: Pearl Stoker, Gail Remus, Tracy Hildebrandt, Maureen Heaman, Dorothy Froman

Other Disciplines

Diana Clarke, Ph.D. in Psychology Robert Minda, Masters in Human Ecology Marcy Pollock, Ph.D. in Management Science

7

Sloan CV, 5/7/2008

Tim Osichuk, Ph.D. in Psychology Bernard Thraves, Masters in Geography Ashwini Kumar, Masters in Agricultural Engineering Leonard Lye Fung Piau, Ph.D. in Civil Engineering

Individual thesis titles for any of the above 80 theses available upon request

d. Education Scholarship e. Honors and Awards for Education f. Academic Career Development

10. INSTITUTIONAL/DEPARTMENTAL ADMINISTRATIVE RESPONSIBILITIES, COMMITTEE

MEMBERSHIPS, AND OTHER ACTIVITIES

2003-present – Mentoring Sub-Committee

2001-present – HSR Education Committee

2000-present – Leader, Mayo Clinic Cancer Center Quality of Life Research Program

11. PRESENTATIONS AT REGIONAL, NATIONAL, AND INTERNATIONAL MEETINGS

386. Sloan JA. Clinical trials and clinical significance for quality of life endpoints in oncology.

University of Minnesota, Minneapolis, MN. February 28, 2007. 385. Sloan JA. What do staticians do? (or at least what I do). Clinical Research Program,

Mayo Clinic, Rochester, MN; January 18, 2007. 384. Petersen LR, Clark MM, Kung S, Novotny P, Sloan JA. Pessimism, depression, and

quality of life in breast cancer survivors (Abstract 861). Psychooncology 2006; 15(Suppl 2):S367.

383. Halyard MY, Jatoi A, Sloan JA, Bearden JD, Fitch TR, Atherton PJ, Buskirk SJ, Soori GS,

Kugler JW, Loprinzi CL, et al. Does zinc sulfate to prevent radiation-induced taste alterations ("dysgeusia") in head and neck cancer patients? A North Central Cancer Treatment Group (NCCTG) placebo-controlled trial (N01C4) (Abstract 2367). Int J Radiat Oncol Biol Phys 2006; 66(3 Suppl):S414.

382. Sloan JA. Monitoring strategies used with clinical trials. ONS Foundation

Interdisciplinary Research Training Program. Washington, DC; October 20, 2006. 381. Sloan JA, Fayers P, Fairclough D, Revicki D. Statistical analysis issues for PROs:

missing data, multiplicity, and longitudinal data structure. ISOQOL, Lisbon, Portugal; October 10, 2006.

380. Sloan JA. Opening Remarks, FDA Guidance on Patient Reported Outcomes:

Discussion, Dissemination, and Operationalization. ISOQOL, Lisbon, Portugal; October 14, 2006.

8

Sloan CV, 5/7/2008

379. Sloan JA, Huschka M, Atherton PJ, Degner L, Hack T, Smith T, Rummans TA, Clark MM. What role do cancer patients want to play in treatment decision making: a pooled analysis. ISOQOL, Lisbon, Portugal; October 10, 2006.

378. Atherton PJ, Smith T, Huntington J, Diekmann BB, Huschka M, Sloan JA. The

relationship between cancer patient treatment decision-making roles and quality of life. ISOQOL, Lisbon, Portugal; October 10, 2006.

377. Sloan JA. Statistics in Clinical Trials by Example: Considerations from a “Real World”

Perspective. Oncology Core Curriculum, Rochester, MN, September 28, 2006. 376. Sloan JA. PRO Assessment in Cancer Symptom Management Trials: The NCCTG

Experience. PROACT Meeting, Bethesda, MD, September 20, 2006. 375. Sloan JA. Overview of Clinical Trial Design. Minority Investigator Career Development

Workshop. Palm Desert, CA, September 5, 2006. 374. Lapid MI, Rummans TA, Brown PD, Frost MH, Johnson ME, Huschka MM, Sloan JA,

Richardson JW, Hanson JM, Clark MM. Impacting the quality of life in elderly cancer patients with a structured multidisciplinary intervention: A randomized controlled trial. Journal of the American Geriatrics Society 2006; 54(4):S196.

373. Yang P, Sun Z, Aubry M, Wampfler J, Jiang R, Garces Y, Jatoi A, Clark M, Sloan JA.

Multi-dimensional prognostic factors for lung cancer (Abstract 93). Am J Epidemiol 2006; 163(11 Suppl): S24.

372. Decker PA, Ballman KV, Locke DE, Brown PD, Jaeckle KA, Buckner JC, Rummans TA,

Clark MM, Sloan JA. Validation of single item Linear Analogue Scale Assessments (LASAs) for assessing quality of life (QOL) in patients with newly diagnosed high-grade gliomas (Abstract 8583): J Clin Oncol 2006; 24(18S): 488s-505s.

371. Sloan JA, Cappelleri J, Nick T, Enders FB, Griswold M. Statistical Consulting for Clinical

Research Invited. Section on Statistical Consulting, Section on Statistical Education. Joint Statistical Meeting, Seattle, Washington; August 9, 2006.

370. Sloan JA. Patient-Reported Outcomes and QOL Issues in Lymphedema Clinical Trials.

GOG Annual Meeting, Washington, DC; July 21, 2006. 369. Sloan JA. Guest lecture for introductory statistics. HSR5530 Introductory Statistical

Methods I. Mayo Clinic; July 17, 2006. 368. Sloan JA, Fayers P, Fairclough D, Revicki D. Statistical Analysis Issues for PROs:

Missing Data, Multiplicity, and Longitudinal Data Structure. ISOQOL Patient-Reported Outcomes & FDA Guidance Meeting. Washington, DC; June 29, 2006.

367. Sloan JA. Assessing Clinical Significance for Quality of Life Measures. University of

Texas. Dallas, TX; May 18, 2006. 366. Sloan JA. Central Nervous System Tumors: Correlates of Clinical Outcomes. ASCO,

Atlanta, GA; June 3-5, 2006. 365. Sloan JA. Statistical Analysis of Patient-Reported Outcome Data. ASCO, Atlanta, GA;

June 3-5, 2006.

9

Sloan CV, 5/7/2008

364. Sloan JA. Clinical Trials in QOL Research. HSR Survey Research Course. Rochester,

MN; April 21, 2006. 363. Sloan JA. Creating a Unified Approach to Patient Reported Outcomes Research, A

Panel Discussion. Patient Reported Outcomes Research Meeting. April 24-25, 2006. Washington, DC.

362. Thompson CA, Cerhan JR, Laplant BR, Maurer MJ, Clark MM, Sloan JA, Rummans TA,

Thomas RJ, Habermann TM. Body mass index (BMI) and physical activity in long-term lymphoma survivors: A pilot study. American Society of Clinical Oncology 2006; Abstract 17511.

361. Swetz K, Moynihan T, Ruegg S, Tan A, Atherton PJ, Sloan J. Providing end-of-life care

to patients seeking hope for cure: Improving Mayo Clinic palliative care utilization. American Society of Clinical Oncology 2006; Abstract 18552.

360. Galanis E, Hartmann LC, Cliby W, Zollman PJ, Peethambaram PP, Long HJ, Kaur JS,

Sloan JA, Peng KW, Russell SJ. Phase I trial of intraperitoneal (IP) administration of a measles virus (MV) derivative expressing the human carcinoembryonic antigen (CEA) in ovarian cancer patients. American Society of Clinical Oncology 2006; Abstract 5028.

359. Atherton PJ, Smith T, Huntington J, Huschka M, Sloan JA. The relationship between

cancer patient tereatment decision-making roles and quality of life (QOL). American Society of Clinical Oncology 2006; Abstract 6075.

358. Mandrekar SJ, Huschka MM, Schaefer PL, Jett JR, Adjei AA, Sloan JA. What is the

value added of patient reported outcomes relative to physician rated symptom assessments? American Society of Clinical Oncology 2006; Abstract 8580.

357. Novotny PJ, Sloan JA, Frost M, Harris M, Huntington J, Chute C, Clement-Brown K. A

population-based study on the quality of life for cancer patients as reported in a tumor registry follow-up. American Society of Clinical Oncology 2006; Abstract 8594.

356. Martenson JA, Sloan JA, Deming RL, Wender DB, Stien KJ, Tai TH, Proulx GM, Zhu AW,

Miller RC, Atherton PJ. Phase III double-blind study of depot octreotide versus placebo in the prevention of acute diarrhea during pelvic radiation therapy: Results of North Central Cancer Treatment Group protocol N00CA. American Society of Clinical Oncology 2006; Abstract 8506.

355. Sloan JA, Huschka M, Atherton P, Degner LF, Hack T, Smith T, Rummans T, Clark M.

What role do cancer patients want to play in treatment decision making: A pooled-analysis. American Society of Clinical Oncology 2006; Abstract 8521.

354. Tan AD, Novotny PJ, Kaur JS, Buckner JC, Schaefer PL, Stella PJ, Sloan JA.

Comparison of baseline quality of life between minority and non-minority patients participating in oncology clinical trials. American Society of Clinical Oncology 2006; Abstract 8527.

353. Jatoi A, Dakhil SR, Kugler JW, Rowland Jr. KM, Keit J, Verdirame JD, Novotny PJ, Sloan

JA, Nguyen L, Loprinzi CL. A placebo-controlled trial of etanercept, a tumor necrosis factor (TNF) inhibitor, in patients with the cancer anorexia/weight loss syndrome. North

10

Sloan CV, 5/7/2008

Central Cancer Treatment Group (NCCTG) trial N00C1. American Society of Clinical Oncology 2006; Abstract 8534.

352. Renno SI, Rao RD, Sloan J, Wong G, Johnson D, Howard GM, Novotny P, Patrick FJ,

Loprinzi CL. The efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: A phase III randomized, double blind, placebo controlled NCCTG trial, N01C3. American Society of Clinical Oncology 2006; Abstract 8530.

351. Barton DL, Loprinzi C, Wender D, Dalton R, Balcueva E, Atherton A, Bernath Jr A, Dekrey

W, Larson T, Bearden III J, Sloan J. Transdermal testosterone in female cancer survivors with decreased libido. American Society of Clinical Oncology 2006; Abstract 8507.

350. Dueck A, Atherton P, Tan A, Sloan J. How much missing data is too much? A single

study exploration. American Society of Clinical Oncology 2006; Abstract 6116. 349. Sloan JA, Watson M, Marino B, Leader S, Riley WT, Bello KR. Panel Discussion:

Creating a Unified Approach to Patient Reported Outcomes Research. Patient Reported Outcomes Research Meeting, April 25, 2006 in Washington, DC.

348. Sloan JA, Cappelleri JC. Workshop: New FDA Draft Guidance Document Review and

Dissemination on Patient Reported Outcomes, Recap of FDA/Mayo Meeting. Patient Reported Outcomes Research Meeting, April 25, 2006 in Washington, DC.

347. Habermann TM, Bauer BA, Janey CA, Rummans TA, Sloan JA, Clark MM, Geyer SM,

Cerhan JR. Beliefs, attitudes and utilization of complementary and alternative medicine (CAM) among long-term lymphoma survivors: a pilot study (Abstract 4700). Blood 2005 Nov; 106(11):2554b

346. Mesa RA, Wadleigh M, Niblack J, Gilliland DG, Verstovsek S, Camoriano J, Solberg L,

Barnes S, Sloan J, Atherton P, Tan A, Tefferi A. Fatigue, the un-addressed curse of myeloproliferative diseases (MPD): results of an international inernet based QOL survey of 830 MPD patients (Abstract 2577). Blood 2005 Nov; 106(11):724a-725a.

345. Sloan JA, Clark MM, Janney CA, Rummans TA, Geyer SM, Cerhan JR, Habermann TM.

Quality of life concerns of long-term lymphoma survivors: results of a pilot study (Abstract 4695). Blood 2005 Nov; 106(11):254b.

344. Sloan J. Post hoc power analysis: an idea whose time has passed? Mayo Clinic SDC

MS/PhD Meeting; January 3, 2006. 343. Dyrbye LN, Thomas MR, Huntington JL, Lawson KL, Novotny PJ, Sloan JA, Shanafelt

TD. Medical student well-being: a multicenter study comparing quality of life, depression, and burnout in minority and non-minority medical students in the U.S. Presented at the Annual Meeting of the Clerkship Directors in Internal Medicine; Portland, OR; October 2005. (CDIM Best Research Poster Award Winner.)

342. Thomas MR, Dyrbye LN, Lawson KL, Huntington JL, Novotny PJ, Sloan JA, Shanafelt

TD. A Multicenter study evaluating the effects of personal well-being on specialty choice among U.S. medical students. Presented at the Annual Meeting of the Clerkship Directors in Internal Medicine; Portland, OR; October 2005. (CDIM Best Research Poster Award Winner.)

11

Sloan CV, 5/7/2008

341. Frost MH, Johnson ME, Sloan J. Improving Spiritual Quality of Life for Patients with Advanced Stage Cancer. October 20, 2005; ISOQOL Conference in San Francisco, CA.

340. Schwartz CE, Arnold D, Gershon R, Varni JW, Kaplan RM, Sloan J, Cella D. Who Owns

the Air We Breathe? Intellectual Property Issues in Patient-Reported Outcome Research. October 20, 2005; ISOQOL Conference in San Francisco, CA.

339. Novotny PJ, Sloan JA. A Comparison of the Old and New SF Scoring Algorithms.

October 20, 2005, ISOQOL Conference in San Francisco, CA. 338. Sloan JA. Mayo & NCCTG QOL Activities. Presented to the United Kingdom National

Cancer Research Institute. October 5, 2005. 337. Sloan JA. Clinical Trials and Clinical Significance for Quality of Life Endpoints in

Oncology. Presented to the Mayo Clinic Thoracic Society; October 10, 2005. 336. Sloan JA. Searching for a relationship between quality of life and genetics. Mechanisms

& Treatment of Cancer-Related Symptoms. Houston, TX; September 10-12, 2005. 335. Sloan JA. Interpreting the Clinical Significance of Results from Patient-Centered

Questionnaires. FDA Industry Statistics Workshop; Washington, DC; September 14-16, 2005.

334. Mesa RA, Wadleigh M, Niblack J, Gilliland, Verstovsek S, Camoriano J, Solberg L, Barnes

S, Sloan J, Atherton P, Tan A, Tefferi A. Fatigue, The Un-Addressed Curse of Myeloprofliferative Disease (MPD): results of an international internet based QOL survey of 830 MPD Patients. ASH, December 2005.

333. Yang P, Sugimura H, Sloan J, Williams B, Cassivi S, Garces Y, Sun Z, Worra J, Midthun

D, Jatoi A. Longitudinal evaluation of quality of life in long-term lung cancer survivors. 11th World Conference on Lung Cancer; Barcelona, Spain; July 3-6, 2005. Lung Cancer 49(Suppl. 2), July 2005.

332. Sloan J. Assessing Clinical Significance for Quality-of-Life Measures. JSM; Minneapolis,

MN; August 9, 2005. 331. Sloan JA. Clinical Trials and Clinical Significance for Quality of Life Endpoints in

Oncology. Moffitt Cancer Center; Tampa, FL; July 28, 2005. 330. Sloan JA. Quality of Life Assessment in Myeloma. MAD DOG Meeting, Mayo Clinic

Rochester, MN; June 22, 2005. 329. Sloan JA. Implementation and Anlalysis of PROs in Clinical Trials. DIA Meeting;

Washington, DC; June 26, 2005. 328. Sloan JA. Quality of Life and Genetics: Is there a relationship? The 5th Annual Jimmie

Holland Lecture, Mayo Clinic Rochester, MN; June 18, 2005.

327. Sloan JA. [TITLE] Presented at Gastroomental Cancer Cooperative and Therapeutics group (GCT) meeting on June 14 at 7 a.m. in Gonda 9-102.

326. West CP, Shanafelt TD, Huntington JL, Kolars JC, Sloan JA, Habermann TM. Medical

knowledge of internal medicine residents is not associated with professionalism or

12

Sloan CV, 5/7/2008

personal wellbeing. AAMC Annual Meeting; Washington, DC; November 7, 2005. 325. Sugimura H., Sloan JA, Williams BA, Cassivi SD, Garces YI, Shifu S, Worra JB, Midthun

DE, Jatoi A, Yang P. Longitudinal Evaluation of Quality of Life in Long-Term Lung Cancer Survivors. IASLC; Barcelona, Spain; July 3-6, 2005.

324. Thompson CA, Shanafelt T, Sloan J, Novotny P, Tan A, Loprinzi C, Moynihan T. Does

participating in clinical trials change the experience of dying for patients with cancer? ASCO, Orlando, FL; May 13-17, 2005. Abstract 8066.

323. Sideras K, Schaefer PL, Okuno SH, Sloan JA, Kutteh L, Fitch TR, DAkhil SR, Levitt R,

Novotny PJ, Loprinzi CL. Phase III clinical trial evaluating low-molecular weight heparin (LMWH) in patients with advanced cancer: A North Central Cancer Treatment Group study. ASCO, Orlando, FL; May 13-17, 2005. Abstract 8186.

322. Morton RF, Sloan JA, Grothey A, Sargent DJ, McLeod H, Green EM, Fuchs C,

Ramanathan RK, Williamson SK, Goldberg RM. A comparison of simple single-item measures and the common toxicity criteria in detecting the onset of oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer. ASCO, Orlando, FL; May 13-17, 2005. Abstract 8087.

321. Carpenter LA, Loprinzi CL, Flynn PJ, Atherton PJ, Barton DL, Shanafelt TD, Rummans

TA, Sloan JA, Adjei AA, Mincey BA. Pilot evaluation of citalopram for alleviation of hot flashes in women with inadequate hot flash control with venlafaxine. ASCO, Orlando, FL; May 13-17, 2005. Abstract 8061.

320. McMillan DE, Schaefer PL, Sloan JA, MOrgenthaler TI, Novotny PJ, Yang P, Huntington

JL, Beardon JD, Mailliard JA, Loprinzi CL. A pooled analysis to estimate the prevalence of sleep complaints among cancer patients. ASCO, Orlando, FL; May 13-17, 2005. Abstract 8053.

319. Steensma DP, Molina R, Sloan JA, Nikcevich DA, Schaefer PL, Rowland KM, Dentchev

T, Tschetter LK, Novotny PJ, Loprinzi CL. A phase III randomized trial of two different dosing schedules of erythropoietin (EPO) in patients with cancer-associated anemia: North Central Cancer Treatment Group (NCCTG) Study N02C2. ASCO, Orlando, FL; May 13-17, 2005. Abstract 8031.

318. Pockaj BA, Gallagher J, Loprinzi CL, Stella PJ, Barton DL, Sloan JA, Rao R, Fitch TR,

Rowland KM, Novotny PJ. Phase III double-blinded, randomized trial to evaluate the use of black cohosh in the treatment of hot flashes: A North Central Cancer Treatment Group study. ASCO, Orlando, FL; May 13-17, 2005. Abstract 8013.

317. Loprinzi CL, Levitt R, Sloan JA, Dakhil SR, Barton DL, Dalton R, Bearden JD, Mailliard

JA, Tschetter LK, Novotny PJ. Medroxiprogesterone acetate (MPA) versus venlafaxine for hot flashes: A North Central Cancer Treatment Group trial. ASCO, Orlando, FL; May 13-17, 2005. Abstract 8014.

316. Wong GY, Michalak JC, Sloan JA, Mailliardy JA, Nikcevich DA, Novotny PJ, Warner DO,

Kutteh L, Dakhil SR, Loprinzi CL. A phase III double blinded, placebo controlled randomized trial of gabapentin in patients with chemotherapy-induced peripheral neuropathy: A North Central Cancer Treatment Group study. ASCO, Orlando, FL; May 13-17, 2005. Abstract 8001.

13

Sloan CV, 5/7/2008

315. Okuno SH, Delaune R, Sloan J, Aubry MC, Foster N, Rowland K, Mailliard J, Nikcevich D, Jett J, Bot B. Gemcitabine and epirubicin in patients with malignant pleural mesothelioma (MPM): A North Central Cancer Treatment Group phase II study. ASCO, Orlando, FL; May 13-17, 2005. Abstract 7264.

314. Sloan JA, Schaefer PL, Witzig TE, Novotny PJ, Silberstein PT, Beardon JD, Allred JB,

Mailliard JA, Loprinzi CL. Relationships among quality of life and survival in anemic patients with advanced cancer undergoing chemotherapy. ASCO; Orlando, FL; May 13-17, 2005. Abstract 6027.

313. Dyrbye LN, Thomas MR, Huntington JL, Lawson K, Novotny P, Sloan J, Shanafelt T. A

multicenter study comparing burnout, depression and quality of life in minority and non-minority medical students in the US. AMEE in Amsterdam, The Netherlands; August 2005. Presenter: Liselotte N Dyrbye.

312. Thomas MR, Dyrbye LN, Lawson KL, Huntington JL, Novotny PJ, Sloan JA, Shanafelt

TD. A Multicenter Study Evaluating the Effects of Personal Well-being on Specialty Choice among U.S. Medical Students. AMEE in Amsterdam, The Netherlands; August 2005.

311. Sloan JA. Spirituality Assessment Presentation. Health Science Research. February

8th, 2005. 310. Sloan JA, Halyard M, Dueck A. Workshop III: Practical Solutions to Quality of Life.

APOS Preconference Training Conference. January 27-29, 2005. 309. Novotny PJ, Sloan JA, Jatoi A, Loprinzi CL, Schaeffer P. Measuring Cancer Patient

Anorexia: A Meta Analysis of NCCTG Anorexia Studies. APOS; Phoenix, AZ; January 27-29, 2005. Abstract S26.

308. Sloan JA, Mcleod H, Sargent D, Zhao X, Fuchs C, Ramanathan R, Williamson S, Findlay

B, Morton R, Goldberg RM. Preliminary Evidence of Relationship between Genetic Markers and Oncology Patient Quality of Life (QOL) Prior to Treatment. APOS, Phoenix, AZ; January 27-29, 2005. Abstract S19.

307. Croghan IT, Sloan J. Nicotine Inhaler vs. Bupropion vs. Nicotine Inhaler plus Bupropion

for Smoking Cessation Efficacy and Relapse Prevention. Presented at SRNT; January 11, 2005.

306. Sloan J. Quality of Life. GI Scientific Leadership Council. Coalition of National Cancer

Cooperative Groups; December 14, 2004. 305. Piderman, Rummans T, Clark M, Sloan J, Atherton P, Frost M. Improving Quality of Life

for Patients with Advanced Cancer with a Structured Multi-Disciplinary Intervention: What We Have Learned about Spiritual Quality of Life and Questions We Ponder. The Second International Conference on Spirituality and Mental Health, University of Ottawa, Ottawa, Ontario, Canada; December 6 & 7, 2004.

304. Sloan J, Kamath CC, Novotny PJ, Barton DL, Bauer BA, Atherton P, Blanch M.

Statistical Issues in the Study of Complementary and Alternative Medicine (CAM) Interventions. National Cancer Institute. Bethesda, MD; November 29-30th, 2001.

303. Sloan JA. Analysis of Clinical Trials. Oncology Core Curriculum; November 24th, 2004.

14

Sloan CV, 5/7/2008

302. Mandrekar S, Sloan J, Dueck A. Quality of Life Assessment – Advances and Future

Developments. MASCC/ISOO Supportive Care in Cancer Conference. Miami Beach, FL; June 24, 2004.

301. Loprinzi C, Levitt R, Barton DL, Sloan J, Atherton P, Smith D, Dakhil S, Moore D Jr, Krook J, Rowland K, Mazurczak M, Berg A, Kim G. Evaluation of Benefin Shark Cartilage in Patients with Advanced Cancer: An NCCTG trial. Society for Integrative Oncology Conference. New York City, NY; November 19th, 2004.

300. Sloan JA. Palliative Care Research Issues and Implications Methods- Sample, setting,

design. International Conference on Malignant Bowel Obstruction: A Model for Randomized Prospective Trials in Palliative Care. Pasadena, CA; November 12-13, 2004.

299. Sloan JA. PRO’s and the FDA. Reaching Patients and Influencing Policy: Improving the

Role of GHO in diseases of Unmet Need. Chapel Hill, NC; November 3, 2004. 298. Atherton PJ, Jasperson B, Nibbe A, Clement-Brown K, Allmer C, Novotny PJ, Erlichman

C, Sloan JA. Use of event charts for summarizing clinically significant changes in oncology quality of life. Qualtiy of Life Research: State of the Science Workshop, San Diego, CA; March 2004.

297. Atherton PJ, Jasperson B, Nibbe A, Clement-Brown K, Allmer C, Novotny PJ, Erlichman

C, Sloan JA. Use of event charts for summarizing clinically significant changes in oncology quality of life. Anuual Clinical Research Conference; August 26-27, 2004.

296. Sloan JA. Quality of Life Assessment Measures for Chronic Disease. Outcomes

Research Committee Meeting; Mayo Clinic Rochester, MN; September 27, 2004. 295. Sloan JA. Genetic Markers and Quality of Life: Preliminary evidence of relationship

between genetic markers and oncology patient quality of life (QOL) (Sloan et al: Abstract #5). Best of ASCO Meeting. Boston, MA; September 17-18, 2004.

294. Atherton PA, Sloan JA, and QOL Team. QOL Presentation. Quality of Life Research:

State of the Science Workshop. San Diego, CA; March 15-16, 2004. 293. Dueck A, Sloan JA, and QOL Team. QOL Analysis. Quality of Life Research: State of

the Science Workshop. San Diego, CA; March 15-16, 2004. 292. Huntington J, Sloan JA, and QOL Team. QOL Examples. Quality of Life Research: State

of the Science Workshop. San Diego, CA; March 15-16, 2004. 291. Sloan JA, and QOL Team. QOL and the FDA. Quality of Life Research: State of the

Science Workshop. San Diego, CA; March 15-16, 2004.

290. Dueck A, Sloan JA, and QOL Team. QOL Assessment Tools. Quality of Life Research: State of the Science Workshop. San Diego, CA; March 15-16, 2004.

289. Sloan JA, and QOL Team. QOL Assessing Clinical Significance. Quality of Life

Research: State of the Science Workshop. San Diego, CA; March 15-16, 2004. 288. Sloan JA, and QOL Team. QOL Background. Quality of Life Research: State of the

15

Sloan CV, 5/7/2008

Science Workshop. San Diego, CA, March 15-16, 2004. 287. Sloan JA, and QOL Team. Introduction. Quality of Life Research: State of the Science

Workshop. San Diego, CA; March 15-16, 2004. 286. Mandrekar S, Sloan JA, and QOL Team. QOL Design. Quality of Life Research: State of

the Science Workshop. San Diego, CA; March 15-16, 2004. 285. Dueck A, Mandrekar S, Novotny P, Atherton P, Sloan J. Quality of Life Endpoints in

Clinical Trials: From Start to Finish. Presented at JSM, Toronto, Canada; August 6, 2004. 284. Huschka M, Atherton P, Novotny P, Maurer M, Parkinson J, Jett J, Sloan J. Qualtiy of

Life measure and toxicity data in a series of north central cancer center treatment group lung cancer clinical trials. Mayo Clinic Research Appreciation Month Poster Fair; August 11, 2004.

283. Novotny PJ, Sloan JA. Measuring Cancer Patient Anorexia: A Meta-Analysis of NCCTG

Anorexia Studies. Mayo Clinic Research Appreciation Month Poster Fair; August 11, 2004.

282. Sloan J, McLeod H, Sargent D, Zhao X, Fuchs C, Ramanathan R, Williomason S, Findlay

B, Morton R, Goldberg RM. Preliminary Evidence of Relationship Between Genetic Markers and Oncology Patient Quality of Life (QOL). Mayo Clinic Research Appreciation Month Poster Fair; August 11, 2004.

281. Rummans TA, Clark MM, Bostwick JM, Sloan J, Frost M, Johnson ME, Miller J,

Richardson J. A structured multidisciplinary intervention improves the QOL of patients with advanced cancer. Mayo Clinic Research Appreciation Month Poster Fair; August 11, 2004.

280. Atherton PJ, Jasperson B, Nibbe A, Clement-Brown KA, Allmer C, Novotny PJ, Erlichman

C, Sloan JA. Use of event charts for summarizing clinically significant changes in Oncology Quality of Life. Mayo Clinic Research Appreciation Month Poster Fair; August 11, 2004.

279. Atherton P, Sloan JA. Integration of Quality of Life into Oncology Clinical Research and

Practice. Mayo Clinic Research Appreciation Month Poster Fair; August 11, 2004. 278. Sloan JA. Overview of Clinical Trial Design. Minority Investigator Career Development

Workshop, Palm Desert, CA; July 22, 2004. 277. Sloan JA, Yeung AS. Alternative reformulations of Cronbach’s Alpha. Proceedings of

the Biometrics Section, ASA; 367-371, 1996. 276. Sloan JA, Kamath CC, Novotny PJ, Barton DL, Bauer BA, Atherton P, Blanch M.

Statistical Issues in the Study of Complementary and Alternative Medicine (CAM) Interventions. The NCI’s Office of Cancer Complementary and Alternative Medicine. Expert Panels in Cancer CAM Research: Developing the State of the Science in Research Methodolgies. Expert Opinions of Methodology: Development of Cancer CAM Sysmptom Research. Bethesda, MD; November 29-30, 2001.

275. McHorney CA, Sloan JA, Revicki DA, Fine LJ, O’Neill RT, Burke LB. Critical Issues for

Developing and Maintaining Item Banks and CATS – Bringing the Concept into Reality:

16

Sloan CV, 5/7/2008

The Idea of a National Item Bank. Presented at DIA IRT CAT Meeting; Bethesda, MD; June 23-25, 2004.

274. Sloan JA, McLeod H, Sargent DJ, Zhao X, Fuchs CS, Ramanathan RK, Williamson SK,

Findlay B, Morton RF, Goldberg RM. Preliminary evidence of relationship between genetic markers and oncology patient quality of life. Abstract 146, ISOQOL 2004 Symposium; Boston, MA; June 27-29, 2004.

273. Atherton PJ, Jasperson BJ, Sloan JA, Mandrekar S, Smith DJ, Erlichman C, Adjei AA. A

Pooled Analysis of Demographic Characteristics and Clinical Outcomes of Phase I Oncology Clinical Trials, The Mayo Clinic Experience. Poster Discussion #9724. 40th Annual ASCO Meeting; New Orleans, LA; June 2004.

272. Mandrekar S, Dy GK, Furth A, Bekele L, Hanson L, Sloan J, Adjei AA. Complementary

and Alternative Medicine (CAM) Use by Patients Enrolled in Phase I Clinical Trials. Poster Discussion #8053. 40th Annual ASCO Meeting;New Orleans, LA; June 2004.

271. Loprinzi CL, Bartson DL, Sloan JA, Novotny PJ, Carpenter L, Gettman M, Christensen

BJ. Pilot Evaluation of Paroxetine for Alleviation of Hot Flashes in Men. Poster Discussion #8016. 40th Annual ASCO Meeting; New Orleans, LA; June 2004.

270. Brown PD, Ballman KV, Rumman TA, Maurer MJ, Sloan JA, Boeve BF, Arusell RM, Clark

MM, Buckner NC. Prospective NCCTG Quality of Life (QOL) Study in Adult Newly Diagnosed High-Grade Gliomas (HGG). Poster Discussion #1524. 40th Annual ASCO Meeting; New Orleans, LA; June 2004.

269. Sloan J, McLeod H, Sargent D, Zhao X, Fuchs C, Ramanathan R, Williomason S, Findlay

B, Morton R, Goldberg RM. Preliminary Evidence of Relationship Between Genetic Markers and Oncology Patient Quality of Life (QOL) Abstract #5. Plenary Session. 40th Annual ASCO Meeting, New Orleans, Louisiana, June 2004.

268. Sloan J. Assessing What Really Matters. Oral Presenation. 40th Annual ASCO Meeting,

New Orleans, LA; June 2004. 267. Stockler MR, Chang VTS, Sloan JA. Design and Analysis of Controlled Trials for

Management of Pain, Depression, and Fatigue. Trial in Cancer Pain, Depression, and Fatigue. Education Session. 40th Annual ASCO Meeting; New Orleans, LA; June 2004.

266. Frost M, Halyard M, Sloan J, Clinical Significance Consensus Writing Team. The Costs

of Incorporating Quality of Life Assessments into Clinical Practice and Research: What Resources are Required? CAPO; Toronto, Canada; May 6 – 8 2004.

265. Frost M, Halyard M, Sloan J, Clinical Significance Consensus Writing Team. A Guide for

Clinicians to Compare the Accuracy and Precision of Quality of Life Data Relative to Other Clinical Measures to Support Medical Decision-Making. CAPO; Toronto, Canada; May 6 – 8 2004.

264. Frost M, Halyard M, Sloan J, Clinical Significance Consensus Writing Team. What is the

Value Added to the Clinician of Applying Quality of Life Information in Clinical Practice? Applying Quality of Life Data Formally and Systematically into Clinical Practice. CAPO; Toronto, Canada; May 6 – 8 2004.

263. Sloan JA. QOL Presentation at daughter’s school; [LOCATION]; April 19, 2004.

17

Sloan CV, 5/7/2008

262. Sloan JA. Will studying Quality of Life improve my quality of life? HSR Survey Research

Course; April 21, 2004. 261. Sloan JA. Quality of Life Research: State of the Science at the Mayo Clinic. Oncology

Seminar; Rochester, MN; April 6th, 2004. 260. Graham KM, Sloan JA. A Randomized, Controlled Two-Period Crossover Clinical Trial to

Assess the Effect of Therapeutic Vibrations from Harp Music Versus Routine Care on Quality of Life for Patients in the Hospital Setting. Mayo Continuing Nursing Education, 2004 Nursing Grand Rounds-Research. Tuesday, March 9, 2004. La Crosse Wisconsin.

259. Sloan JA. Clinical Trials in Symptom Research Presentation. Mechanisms and

Treatment of Cancer Related Symptoms Conference. MD Anderson, Houston, Texas, February 20-22, 2004.

258. Sloan JA, Cella D, Frost MH, Guyatt G, Osoba D. Translating the Science of Quality of

Life Assessment into Clinical Practice. APOS First Annual Conference. February 2, 2004.

257. Osoba D. for Sloan JA, Cella D, Frost MH, Guyatt G and the Clinical Consensus Meeting

Group. Translating the Science of Health-Related Quality-of-Life (HRQOL) Assessment into Clinical Practice. Mayo Alumni Association Conference, Scottsdale, Arizona; October 3, 2003.

256. McMillan DE, Sloan JA, Richardson J, Frost MH, McClement S, Morre W, Novotny PJ,

Painter V, Read L. Linking clinical significance to a sleep intervention model. Clinical Ther. 2003; 25 Suppl D:D45-7.

255. Garces YI, Yang P, Parkinson J, Zhao X, Novotny PJ, Wampfler JA, Ebbert JO, Sloan

JA. Does cigarette smoking have an impact on quality of life after diagnosis of lung cancer? Clinical Ther. 2003;25 Suppl D:D33-4.

254. Chauhan C, Eppard W, Frost MH, Halyard M, Sloan JA. The patient's perspective of

quality of life assessments. Clinical Ther. 2003;25 Suppl D:D11. 253. Sloan JA, Moinpour C, Berzon R, Bullinger M, Barofsky I, Wu AW. The costs of

incorporating quality of life assessments into clinical practice and research: What resources are required? Clinical Ther. 2003;25 Suppl D:D9.

252. Sloan JA, Cella D, Frost MH, Guyatt G, Osoba D; Clinical Significance Consensus

Meeting Group. Quality of life III: translating the science of quality of life assessment into clinical practice an example driven approach for practicing clinicians and clinical researchers. Clinical Ther. 2003;25 Suppl D:D1-5.

251. Sloan, J. What Is "Minimal Clinically Important Difference?" Scientific Perspective.

Presented at Minimal Clinically Important Differences in COPD, January 12, 2004. 250. Habermann TM, West CP, Kolars JC, Sloan JA, Novotny PJ, Zhao X. Association

between resident well-being and competency in professionalism and interpersonal skills. Poster Presentation at ACGME, March 3-5, 2004.

249. Sloan, J. A Structured Multidisciplinary Psychosocial Intervention Improves the Quality of

18

Sloan CV, 5/7/2008

Life of Patients with Advanced Cancer. Presented at ISOQOL; November 15, 2003. 248. Sloan J, Frost M, Halyard M. Translating the Science of QOL Assessment into Clinical

Practice: An Example-Driven Approach for Practicing Clinicians and Clinical Researchers. Presented at ISOQOL; November 13, 2003.

247. Sloan J, Frost M. Assessing the clinical significance for QOL measures in oncology

research. Presented at Psychosocial Oncology and Palliative Care Symposium; October 23, 2003.

246. Graham K, Schneider D, Novotny P, Parkinson J, Sloan JA. Use of music to improve

hospitalized patients’ quality of life. Presented Department of Health Sciences Research; September 26, 2003.

245. Sloan JA, Cappelleri JC, Scott CB. Methods for Assessing Clinical Significance in Quality

of Life Measurement. Presented Biometrics Section; August 3, 2003. 244. Sloan JA. Oral Presentation: Patient Care. Presented at ASCO Annual Meeting; June 1,

2003. 243. Sloan A. Meet the Professor: Research Seminar: Assessing Clinical Significance in

Measuring Quality of Life for Patients with Cancer. Presented at ASCO Annual Meeting; May 31, 2003, and June 2, 2003.

242. Sloan JA. Advances in Quality of Life Research. Presented at Patient Advocate

Symposium, Rochester, MN; June 18, 2003. 241. Novotny PJ, Sloan J, Guse L, Alberts SR, Goldberg R, Gregory D, Hartmann L, Johnson

M, Rummans T. A pilot study assessing social support among cancer patients enrolled on clinical trials: a comparison of younger versus older adults. Abstract, Proceedings of ASCO Chicago, IL, 22(2992):744, May 31, 2003.

240. Jatoi A, Rowland KM, Loprinzi CL, Sloan JA, Dakhil SR, MacDonald N, Gagnon B,

Novotny PJ, Malliard JA, Krook JE. An eicosapentainoic acid (EPA)-enriched supplement versus megastrol acetate (MA) versus both for patients with cancer-associated wasting. Abstract, Proceedings of ASCO Chicago, IL; 22(2987):743, May 31, 2003.

239. Shanafelt TD, Loprinzi C, Marks R, Sloan J. Relationship between response rate and

survival. Abstract, Proceedings of ASCO Chicago, IL; 22(2983):742, May 31, 2003. 238. Sloan JA, Rummans T, Clark M, Frost M, Atherton P, Bostwick M, Gamble G, Johnson

M, Martenson J, Richardson J. A structured multidisciplinary psychosocial intervention improves the quality of life of patients with advanced cancer. Abstract, Proceedings of ASCO Chicago, IL; 22(2925):727; May 31, 2003.

237. Blanch MM, Atherton PJ, Novotny PJ, Maurer MJ, Parkinson J, Jett J, Sloan J. Less is

more III: Quality of life measures and toxicity data in a series of North Central Cancer Treatment Group (NCCTG) lung cancer clinical trials. Abstract, Proceedings of ASCO Chicago, IL; 22(2124):528; May 31, 2003.

236. Bible KC, Lensing JL, Nelson SA, Atherton PJ, Sloan JA, Erlichman C. A phase 1 trial of

flavopiridol combined with 5-fluoroualcil (5FU) and leucovorin (CF) in patients with advanced malignancies. Abstract, Proceedings of ASCO Chicago, IL, 22(872):218, May

19

Sloan CV, 5/7/2008

31, 2003. 235. Sloan JA. Research Seminar: Assessing Clinical Significance in Measuring Quality of

Life for Patients with Cancer. Presented at 39th annual meeting ASCO, Chicago, IL; May 31, 2003.

234. Sloan, JA. Assessing the Clinical Significance for Patient-Reported Outcomes: What is

the State of the Science? Presented at the FDA Division Directors dinner meeting, February 21, 2003 in Bethesda, MD.

233. Blanch M, Atherton P, Novotny P, Maurer M, Parkinson J, Sloan J. Single versus

multiple item quality of life measures in a series of North Central Cancer Treatment Group (NCCTG) clinical trials. Oral presentation at ISOQOL, Orlando, FL; November 1, 2002.

232. Barton DL, Loprinzi CL, Novotny P, Sloan J, Christiansen B. Long term follow up with

Venlafaxine for hot flash management. Presented at the 28th Annual Congress called “Climbing our Mountains,” Denver, CO; May 1, 2003.

231. Barton D, Loprinzi C, Novotny P, Parkinson J, Sloan, JA. Relief from hot flashes: defining

distress and satisfaction. Presented at the 28th Annual Congress called “Climbing our Mountains,” Denver CO; May 1, 2003.

230. Sloan, JA. Methods for assessing clinical significance in quality of life measurement.

Invited Symposium. 6th World Congress of Psycho-Oncology; Banff, Alberta, Canada; April 23-27, 2003.

229. Sloan JA. Practical applications of outcomes research. Outcomes Research Meeting,

Philadelphia, PA; March 18, 2003. 228. Sloan JA. Methodological and Philosophical issues in assessing the clinical significance

of patient-reported outcomes. DIAQOL Baltimore, MD; March 16, 2003. 227. Sloan JA. Methods for assessing clinical significance of quality of life measures. 2003

San Francisco Conference Radiation Oncology; March 1, 2003. 226. Sloan JA, Sargent DJ, Atherton Skaff P, Allmer C, Loprinzi CL. A simple approach for

defining clinically relevant effects in quality of life measures. Cancer Care and Therapeutics Conference, Chicago, IL; November 13, 1998.

225. Sloan JA, Atherton Skaff PJ, Reid J, Pitot H, Erlichman C, Schaaf L. Limited sampling

models for irinotecan pharmacokinetics. American Society for Clinical Pharmacology and Therapeutics 65(2):197, San Antonio, TX; March 18-21, 1999.

224. Sloan JA, Sargent D, Atherton Skaff P, Allmer C. Searching for clinically relevant effects

in QOL instruments. DIAQOL, Hilton Head, SC; March 29, 1999. 223. Pitot HC IV, Erlichman C, Reid JM, Sloan JA, Ames MM, Bagniewski PG, Atherton Skaff

P, Adjei AA, Rubi J, Rayson D, Goldberg RM. A phase I study of bizelesin (NSC615291) in solid tumors. AACR Annual meeting; Philadelphia, PA; April 10-14, 1999.

222. Klein C, Gupta E, Reid J, Pitot H, Atherton P, Sloan J, Ratain M, Kastrissios H.

Development and vallidation of a model for the disposition of irinotecan (CPT11) and its metabolites over a wide range. American Society for Clinical Pharmacology &

20

Sloan CV, 5/7/2008

Therapeutics 67(2):102;Los Angeles, CA; March 14-18, 2000. 221. Sloan JA, Sargent D, Atherton Skaff P, Allmer C. Searching for clinically relevant effects

in QOL instruments. Mayo Clinic Cancer Center Psycosocial Oncology Symposium; Rochester, MN; April 3, 2000.

220. Rubin J, Hartmann LC, Sloan JA, Atherton PJ, Erlichman C, Adjei AA. A phase I and

pharmacology study of sequences of vinorelbine and paclitaxel in patients with advanced solid tumors. American Society of Clinical Oncology; New Orleans, LA; May 20-23, 2000.

219. Alberts SR, Erlichman C, Sloan JA, Atherton PJ, Okuno SH, Burch PA, Kaufmann SH.

Phase I trial of gemcitabine (GEM) and irinotecan (CPT11) given weekly x 4 every 6 weeks. American Society of Clinical Oncology; New Orleans, LA; May 20-23, 2000.

218. Reid JM, Adjei AA, Sloan JA, Diasio RB, Smith DA, Rubin J, Pitot HC, Alberts SR,

Goldberg RM, Hanson LJ, Atherton P, Ames MM, Erlichman C. A comparison pharmacokinetic study of continuous venous infusion (CVI) 5-fluorouracil and oral 5-fluorouracil with the dihydropyrimidine dehydrogenase (DPD) inactivator eniluracil in patients with advanced solid tumors. American Society of Clinical Oncology, San Francisco, CA; May 13-15, 2001. Abstract 357, P90a.


C, Sloan JA. So what happened to all the patients? Event charts for summarizing clinically significant changes on oncology quality of life data. Poster Presentation, North Central Cancer Treatment Group (NCCTG) Semiannual meetings, Mayo Clinic, Rochester, MN; April 24-27, 2001.


C, Sloan JA. So what happened to all the patients? Event charts for summarizing clinically significant changes on oncology quality of life data. Poster Presentation, Assessing Clinical Significance for Quality of Life Measures in Oncology Research: State-of-the-Science, Mayo Clinic; Rochester, MN; April 5-6, 2002.


C, Sloan JA. So what happened to all the patients? Event charts for summarizing clinically significant changes on oncology quality of life data. Published abstract. Clinical Therapeutics, Assessing Clinical Significance for Quality of Life Measures in Onconology Research: State-of-the-Science 24:48-49, 2002.

214. Sloan JA. Psychosocial Aspects of Cancer. Presented at the Cancer Conference, 2001. 213. Sloan JA. Assessing the Clinical Significance of Quality of Life (QOL) Measures: What

good is QOL anyway? Presented SoCRA 11th Annual Conference; 2002. 212. Sloan JA. Methods for Assessing Clinical Significance of Quality of Life Measures

(worms, ducks, and elephants) Presented Bristol Meyers Squibb, 2002. 211. Bruce BK, Frost MH, Moynihan TJ, Piderman MAK, Sloan JA. Moving the Spiritual

Research Question. Mayo Clinic Panel Members, Mayo Foundation for Medical Education and Research 291; 2002.

210. Allred JB, Novotny PJ, Sloan JA, Clement-Brown KA, Baker BA, Witzig TE, Loprinzi CL.

Results from a Phase III Randomized Double-Blind Study of Erythropoietin (EPO) Versus

21

Sloan CV, 5/7/2008

Placebo in Anemic Patients with Cancer Undergoing Chemotherapy. Abstract Issue, 9th Annual Conference of the International Society for Quality of Life Research, Oct. 30 - Nov 2, 2002, Orlando, FL. Quality of Life Research 11(7):680 2002.

209. Blanch MM, Atherton PJ, Novotny PJ, Maurer MJ, Sloan JA. Comparison of Singer

Versus Multiple Item Quality of Life Measures in a Series of North Central Cancer Treatment Group (NCCTG) Cancer Clinical Trials. Abstract Issue, 9th Annual Conference of the International Society for Quality of Life Research, Oct. 30 - Nov 2, 2002; Orlando, FL; Quality of Life Research 11(7): 2002.

208. Sloan JA. Methods for Assessing Clinical Significance of Quality of Life Measures

(Worms, Ducks, and Elephants). Presented at Bristol-Myers Squibb; October 3, 2002. 207. Sloan JA, Aziz N, Schwartz M, Andrykowski M. Psychosocial Aspects of Cancer.

Presented at Using Science to Build Comprehensive Cancer Programs; September 6, 2001.

205. Sloan JA. Assessing the Clinical Significance of Quality of Life (QOL) Measures: What

Good is QOL Anyway? Presented at SoCRA 11th Annual Conference Philadelphia, PA; September 22, 2002.

204. Kanard A, Hillman S, Stella P, Mailliard J, Sloan JA, Vanone S, Cannon M, Kutteh L, Jett

J, Jatoi A. Activities of Daily Living (ADL): Exploring their Spectrum and Prognostic Impact Prospectively in Older, Non-Small Lung Cancer (NSCLC) Patients. A North Central Cancer Treatment Group Investigation. American Society of Preventive Oncology; March 2003.

203. Sloan JA, Frost M. Assessing the Clinical Significance for QOL Measures in Oncology

Research. Presented at Psychosocial Oncology Skill Building Meeting; Toronto, Canada; September 13, 2002.

202. Sloan JA, Frost M, Osoba D, Berzon R. Methods for Assessing Clinical Significance in

Quality of Life Measurement. Presented at DIA; Chicago, IL; June 17, 2002. 201. Erlichman C, Goldberg RM, Sloan JA, Reid JM, Adjei AA, Atherton PJ, Windebank AJ,

Hanson LJ. Phase I Study of the Combination of CPT-11/5FU/leucovorin/oxaliplatin. Presented at ASCO; May 2002.

202. Silberstein PT, Witzig TE, Sloan JA, Mailliard JA, Rowland KM, Krook JE, Ghosh C,

Steen PD, Loprinzi CL. Weekly Erthropoietin for Patients with Chemotherapy Induced Anemia: a Randomized, Placebo-controlled Trial in the North Central Cancer Treatment Group. Presented at ASCO, May 2002.

199. Loprinzi CL, Barton DL, Sloan JA, Zahasky KM, Smith D, Pruthi S, Novotny PJ, Perex

EA. Pilot Evaluation of Gabapentin for Alleviation of Hot Flashes. Presented at ASCO; May 2002.

198. Jacobson SD, Loprinzi CL, Sloan JA, Wilke JL, Novotny PJ, Okuno SH, Jatoi A,

Moynihan TJ. Glutamine for Preventing Paclitaxel-associated Myalgias and Arthralgias: Unfortunately a “No Go.” Presented at ASCO; May 2002.

197. Barton DL, Loprinzi CL, Sloan JA, Dakhil SR, Collins ML, Martin LS, Pockaj B, Novotny

PJ, Rummans TA. Pilot Evaluations of Newer Antidepressants for Hot Flashes.

22

Sloan CV, 5/7/2008

Presented at ASCO; May 2002. 196. Sloan JA, Novotny P, Bass E, Loprinzi CL, Varricchio C. Do Improvements in Patient-

reported Toxicities Relate to Improved Overall Quality of Life? A Comparison of Symptom Assessment Methods. Presented at ASCO; May 2002.

195. Fairclough D, Sloan JA, Aaronson N, Cappelleri JC, Varricchio C. Assessing the Clinical

Significance of Single Item Quality of Life Measures Relative to Summated Scores. Presented at ASCO; May 2002.

194. Goetz MP, Rubin J, Callstrom MR, Charboneau JW, Wong GY, Sloan JA, Novotny PJ, Lewis BD, Welch TJ, Farrell MA, Maus TP, Lee Ram Reading CC, Saker MB, Nemcek AA, Petersen IA. Precrutaneous US and CT-guided Radiofrequency Ablation of Painful Metastases Involving Bone. Presented at ASCO; May 2002.

193. Varricchio CG, Bass E, Novotny P, Loprinzi CL, Jett J, Sloan JA. Common Toxicity

Criteria Versus Symptom Specific Measures: How Congruent are the Data? Presented at ASCO, May 2002.

192. Sloan, JA. Assessing Clinical Significance for QOL Measures in Oncology Research:

State of the Science. Presented at the Psychosocial symposium; April 29, 2002. 190. Sloan J, Symonds T. Assessing clinical significance for QOL measurement. Presented

at the 8th Annual Conference of the International Society for Quality of Life Research, Amsterdam, The Netherlands; November 7-10, 2001.

189. Sloan JA, Guyatt G, Bullinger M, Frost M, Sprangers M, Symonds T. Clinical significance

of HRQL outcomes. Presented at the 8th Annual Conference of the International Society for Quality of Life Research, Amsterdam, The Netherlands; November 7-10, 2001.

188. Sloan JA, Frost MH. Utilization of Quality of Life (QOL) Measures in Cancer Care: A

Report on a QOL Consensus Conference. Presented at 2001 Current Issues in Cancer Care; Rochester, Minnesota; September 24, 2001.

187. Cuddihy MT, Melton III J, Sloan JA, Crowson CS, Gabriel SE. Predictors of quality of life

in postmenopausal women after low impact distal forearm fracture. Presented at ACR 65th Annual Scientific Meeting; 2001.

186. Chappell R, Fairclough D, Sloan J, Zee B. Analytical issues related to quality-of-life data.

Workshop presented at the Society for Clinical Trials, 22nd Annual Meeting; Denver, CO; May 20-23, 2001.

185. Sloan JA. Will studying Quality of Life improve my quality of life? Presented to Health

Services Research Statistics Class, HSR 5000; May 9, 2001. 184. Sloan JA. But what does it mean? Assessing clinical significance of quality of life

measurements. Presented at the Psychosocial Oncology and Medicine: Sharing Common Ground Conference, Winnipeg, Manitoba, Canada; May 2-5, 2001.

183. Kaur JS, Roubidoux M, Sloan J, Novotny P. Biological risks for breast cancer in

American Indian and Alaska Natives. Presented at the 7th RCMI International Symposium on Health Disparities, San Juan, Puerto Rico, November 14, 2000.

23

Sloan CV, 5/7/2008

182. Frost MH, Sloan JA, Symonds T, Cella D, Sprangers M, Guyatt G. Assessing clinical significance in oncology quality of life measurement. Presented at the American Society of Clinical Oncology, San Francisco, CA, May 12-15, 2001.

181. Sloan JA, Loprinzi CL, Novotny PJ, Barton DL, Windschitl HE. Methodological lessons

learned from oncology patient hot flash (HF) studies. Presented at the American Society of Clinical Oncology, San Francisco, CA, May 12-15, 2001.

180. Atherton PJ, Novotny PJ, Jasperson B, Nibbe A, Clement-Brown KA, Erlichman C, Sloan

JA. So what happened to all the patients? - Event charts for summarizing clinically significant changes in oncology quality of life data. Presented at the American Society of Clinical Oncology, San Francisco, CA, May 12-15, 2001.

179. Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Johnson DB, Mailliard JA, Pundaleeka S,

Kardinal CG, Fitch TR, Krook JE, Novotny PJ, Christensen B. Donabinol versus Megestrol Acetate versus both for cancer-associated anorexia: a North Central Cancer Treatment Group Study. Presented at the American Society of Clinical Oncology, San Francisco, CA, May 12-15, 2001.

178. Kozelsky T, Martenson J, Sloan J, Meyers G, Rowland K, Michalak J, Levitt R, Schaefer

P, Mailliard J, Morton R, Krook J, Stella P, Loprinzi C. Phase III double-blind study of Glutamine versus placebo for the prevention of acute diarrhea in patients receiving pelvic radiation therapy. Presented at the American Society of Clinical Oncology, San Francisco, CA, May 12-15, 2001.

177. Bonner JA, Sloan J, Hillman S, Vigliotti AP, Kozelsky TF, Marks RS, Frank AR, Graham

DL, Mailliard JA, Jett JR, Levitt R, Fishkin P. A phase II study of high dose twice-daily thoracic radiation therapy with concomitant cisplatin/etoposide in limited stage small cell lung cancer. Presented at the American Society of Clinical Oncology, San Francisco, CA, May 12-15, 2001.

176. Pitot HC, Adjei AA, Reid JM, Sloan JA, Goldberg RM, Rubin J, Alberts SR, Duncan BA,

Eli MP, Schaaf LJ, Knight RD, Archinal AE, Miller LL, Erlichman C. A phase I and pharmacokinetic study of a powder-filled capsule (PFC) formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors. Presented at the American Society of Clinical Oncology, San Francisco, CA, May 12-15, 2001.

175. Reid JM, Adjei A, Sloan J, Diasio R, Smith DA, Pitot H, Rubin J, Alberts S, Goldberg R. A

comparative pharmacokinetic study of continuous venous infusion (CVI) 5-Fluorouracil and oral 5-Fluorouracil with the dihydropyrimidine dehydrogenase (DPD) inactivator eniluracil in patients with advanced solid tumors. Presented at the American Society of Clinical Oncology, San Francisco, CA, May 12-15, 2001.

174. Erlichman C, Adjei AA, Thomas JP, Wilding G, Reid JM, Sloan JA, Atherton P, Hanson

LJ, Alberti D, Kaufmann SH, Elliott P. A phase I trial of the Proteasome Inhibitor PS-341 in patients with advanced cancer. Presented at the American Society of Clinical Oncology, San Francisco, CA, May 12-15, 2001.

173. Adjei AA, Erlichman C, Marks RS, Croghan GA, Sloan JA, Hanson LJ, Reid JM, Atherton

PJ, Pitot HC, Alberts SR, Seifert WF, Thibault A, Kaufmann SH. A Phase I trial of the Farnesyltransferase inhibitor R115777, in combination with Gemcitabine and Cisplatin in patients with advanced cancer. Presented at the American Society of Clinical Oncology,

24

Sloan CV, 5/7/2008

San Francisco, CA, May 12-15, 2001. 172. Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ, Mailliard JA, Halyard MY, Pruthi

S, Novotny PJ, Rummans TA. Fluoxetine reduces hot flashes. Presented at the American Society of Clinical Oncology, San Francisco, CA, May 12-15, 2001.

171. Cuddihy MT, Gabriel SE, Crowson CS, Sloan JA, Melton LJ. Impact of osteoporosis

health beliefs on preventive behaviors in the postmenopausal post-fracture patient. Presented at the American Society for Bone and Mineral Research. [DATE]

170. Sloan JA. Methods for assessing clinical significance in quality of life measurement.

Presented at Psychosocial Oncology Symposium; April 2, 2001. 169. Atherton PJ, Jasperson B, Nibbe A, Clement-Brown K, Novotny PJ, Erlichman C, Sloan

JA. So what happened to all the patients? Event charts for summarizing clinically significant changes on oncology quality of life data. Society for Clinical Trials, 22nd Annual Meeting, Denver, CO; May 20-23, 2001.

168. Atherton PJ, Jasperson B, Nibbe A, Clement-Brown K, Novotny PJ, Erlichman C, Sloan

JA. So what happened to all the patients? Event charts for summarizing clinically significant changes on oncology quality of life data. American Society of Clinical Oncology, San Francisco, CA; May 13-15, 2001.

167. Atherton PJ, Jasperson B, Nibbe A, Clement-Brown K, Novotny PJ, Erlichman C, Sloan

JA. So what happened to all the patients? Event charts for summarizing clinically significant changes on oncology quality of life data. Drug Information Association, QOL, Hilton Head, SC; March 25-27, 2001.

166. Sloan J. Methods for assessing clinical significance of quality of life measures. 8th

Annual Symposium of Contributed Papers on Quality of Life Evaluation. The Westin Resort, Hilton Head Island, SC; March 26, 2001.

165. Sloan J. Measurement issues in medical research. HSR 5708, Course Lecture, March

14, 2001. 164. Sloan J. Analysis of clinical trials. Oncology Core Curriculum Course Lecture; August 2,

2000. 163. Sloan J. Massage therapy in palliative care: Literature review and research issues.

Minnesota Elderhostel Meeting, Rochester Community Technical College; November 9, October 17, August 14, July 18, 2000.

162. Sloan J, Symonds T. Clinical and statistical significance: differences and similarities.

Workshop presented at the ISOQOL Methods Workshops; Washington, DC; February 5-6, 2001.

160. Erlichman C, Toft DO, Reid JM, Sloan JA, Atherton PJ, Adjei A, Ames M, Croghan GA. A

Phase I trial of 17-Allyl-Amino-Geldanamycin in patients with advanced cancer. Presented at the AACR Annual Meeting in New Orleans, LA; 2001.

159. Sloan JA. Recruiting and Retaining Study Subjects. Presented at the Practical Aspects

of Patient-Oriented Research Lecture; Rochester, MN; December 22, 2000.

25

Sloan CV, 5/7/2008

158. Atherton PJ, Novotny PJ, Clement-Brown KA, Sloan JA. So what happened to all the patients? Event charts for summarizing clinically significant changes in oncology quality of life data. Presented at the 7th Annual Conference of the International Society for Quality of Life Research; Vancouver, Canada; October 29-31, 2000.

157. Osoba D, Sloan JA, Sprangers M. Masters Lecture: Quality of Life Measurement:

Methods for assessing clinical significance in quality of life measurement. Presented at the 7th Annual Conference of the International Society for Quality of Life Research; Vancouver, Canada;October 29-31, 2000.

156. Sloan J, Symonds T. Assessing clinical significance for QOL measurement. Presented

at the 7th Annual Conference of the International Society for Quality of Life Research, Vancouver, Canada; October 29-31, 2000.

155. Bonner JA, Sloan JA, Marks MS, Kozelsky TF, Vigliotti AP. High dose thoracic radiation

therapy with concomitant cisplatin/etoposide and early prophylactic cranial irradiation in limited stage small cell lung cancer. Presented at the 41st Annual ASTRO Meeting, Orlando, FL; November 2-6, 1999.

154. Zahasky KM, Loprinzi CL, Sloan JA, Novotny PJ, Quella SK. Detailed prospective data

regarding tamoxifen-associated “hot flashes.” Mayo Clinic Cancer Center Women’s Cancer Program: Research Update 1999; Rochester Marriott Hotel, Rochester, MN, October 8, 1999.

153. Sloan JA, Loprinzi CL, Novotny PJ, Okuno S, Nair S, Barton DL. Gender differences in

5FU-induced stomatitis. Mayo Clinic Cancer Center Women’s Cancer Program: Research Update 1999, Rochester Marriott Hotel, Rochester, MN, October 8, 1999.

152. Loprinzi CL and colleagues. Studies regarding the use of newer antidepressants for

alleviating “hot flashes.” Mayo Clinic Cancer Center Women’s Cancer Program: Research Update 1999, Rochester Marriott Hotel, Rochester, MN, October 8, 1999.

151. Erlichman C, Adjei A, Sloan J, Pitot H, Goldberg R, Peethambaram P, Alberts S, Galanis

E, Hanson L, Reid J, Rubin J, Burch P, Thornton D, Walling J. A phase I trial of MTA and Gemcitabine. Mayo Clinic Cancer Center Women’s Cancer Program: Research Update 1999, Rochester Marriott Hotel, Rochester, MN, October 8, 1999.

150. Bonner JA, Sloan J, Hillman S, Vigliotti APG, Kozelsky TK, Marks RS, Frank AR, Graham

DL, Mailliard JE, Jett JR, Levitt R, Kugler JW. A phase I/II study of high dose twice-daily thoracic radiation therapy with concomitant cisplatin/etoposide in limited stage small cell lung cancer. Presented at American Society of Clinical Oncology; May 2001.

149. Croghan IT, Croghan GA, Hurt RD, O’Hara M, Novotny PJ, Sloan JA, Patten CA, Bowen

D, Valentine S, Dale LC, Hays JT. Teens and adults view smoking differently: Results of a contest for Middle School students to develop recruitment messages for smoking cessation programs. Sixth International Congress of Behavorial Medicine, Brisbane, Australia, November 15-17, 2000.

148. Sloan JA. Quality of life measures and clinical significance. Presented at Integrative

Cancer Care, Phillips Hall, Siebens Medical Education Building, Rochester, Minnesota, October 20-21, 2000.

147. Midthun DE, Swensen SJ, Jett JR, Sloan JA, Hartman TE, Sykes AM, Augenbaugh GL,

26

Sloan CV, 5/7/2008

Hillman SL. Screening for lung cancer with low-dose spiral computed tomography. Presented at the American Thoracic Meeting, May 2001.

146. Erlicman C, Toft D, Reid J, Sloan J, Atherton P, Adjei A, Ames M, Croghan G. A Phase I

trial of 17-Allyl-Amino-Geldanamycin in patients with advanced cancer. Presented at 92nd Annual AACR Meeting, March 2001.

145. Fairclough DF, Sloan JA. Imputation for non-randomly missing QOL data in longitudinal

studies. Invited Workshop Presented for the International Society for Quality of Life Research, Tysons Corner, January 11, 2000.

144. Fairclough DF, Sloan JA. Analysis of longitudinal studies with missing data. Invited

Workshop Presented for the International Society for Quality of Life Research, Tysons Corner, January 10, 2000.

143. Adjei AA, Erlichman C, Sloan JA, Hanson LJ, Reid J, Atherton P, Geary R, Holmlund J,

Dorr A. A Phase I trial of ISIS 2503, and antisense inhibitor of H-ras in combination with gemcitabine in patients with advanced cancer. Presented at American Society of Clinical Oncology, May 20-23, 2000.

142. Erlichman C, Rubin J, Hartmann LC, Sloan JA, Atherton PJ, Adjei AA, Reid JM. A Phase

I and pharmacology study of vinorelbine and paclitaxel in patients with advanced solid tumors. Presented at American Society of Clinical Oncology, May 20-23, 2000.

141. Sloan JA, Goldberg R, Sargent DJ, Nair S, Cha SS, Novotny PJ, O’Connell MJ, Jatoi A,

Loprinzi CL. Women experiencing greater toxicity with 5FU-based chemotherapy (CTX) for colorectal cancer (CC): A North Central Cancer Treatment Group (NCCTG) Meta-Analysis. Presented at American Society of Clinical Oncology, May 20-23, 2000.

140. Loprinzi CL, Kugler JW, Sloan J, Mailliard JA, LaVasseur B, Barton D, Novotny P, Dakhil

S, Kardinal CG, Christensen BJ, Rodger K, Rummans TA. Venlafaxine alleviates hot flashes: A NCCTG Trial. Presented at American Society of Clinical Oncology, May 20-23, 2000.

139. Sloan JA. Will studying quality of life improve my quality of life? Presented at Health

Sciences Research 5000, Mayo Clinic, May 10, 2000. 138. Sloan JA, Novotny PJ, Loprinzi CL. Design and analysis of cancer control studies using

the SAS system. Presented at SUGI 25, Indianapolis, Indiana, April 9-12, 2000. 137. Sloan JA, Novotny PJ, Sargent DJ, Atherton Skaff P, Allmer C, Loprinzi CL. Defining

clinically relevant effects in quality of life measures. Presented at Mayo Clinic Cancer Center Psychosocial Oncology Symposium, April 3, 2000.

136. Chelf JH, Kroshus ME, Sloan JA, Novotny PJ, Dowdy JL, Thiemann KM, Deshler AM.

Reading ability of adult patients receiving care at an NCI Comprehensive Cancer Center: An exploratory comparative study. Presented at Cancer, Culture & Literacy, Moffitt Cancer Center, Tampa, FL; May 5, 2000.

135. Sloan JA. Will You Share Your Pain: Quality of Life Research Issues. Presented at

Winona State Graduate Nursing Students Seminar, March 27, 2000. 132. Frost MH, Woods JE, Slezak J, Schaid DJ, Sloan J, Johnson JL, Sellers TA, Jenkins RB,

27

Sloan CV, 5/7/2008

Hartmann, LC. Bilateral prophylactic mastectomy (PM): long-term satisfaction, psychological and social function. Presented at 6th Annual Conference of the International Society for Quality of Life Research, Barcelona, Spain, November 3-6, 1999.

132. Jett JR, Swensen SJ, Midthun DE, Hartman TE, Sykes AM, Aughenbaugh GL, Halling

AC, Tazelaar HD, Sloan JA. Screening for lung cancer: Mayo Clinic study with low-dose spiral CT scan (SCT) and sputum cytology (prevalence screen). Presented at Society Clinical Trials, Toronto, Ontario, Canada, May 5-10, 2000.

131. Sloan JA. Status of small cell lung cancer. Audio Broadcast on November 10, 1999,

8:00 p.m. ET. 130. Sloan JA. Missing data in clinical trials: Basic approaches. Presented at the 1999

International Conference on Health Policy Research, Santa Monica, California, December 3-5, 1999.

129. Sloan JA. Statistical consultation in clinical research. Presented at GCRC Lecture-This

Week, Mayo Clinic; Rochester, MN; November 18, 1999. 128. Sloan JA, Atherton Skaff P, Yeung A, Allmer C. Mathematical realities of Cronbach’s

alpha coefficient as a measure of quality of life instrument reliability. 6th Annual Conference of the International Society for Quality of Life Research; Barcelona, Spain; November 3-6, 1999.

127. Jett JR, Swensen SJ, Midthun DE, Hartman TE, Sykes AM, Aughenbaugh GL, Halling

AC, Tazelaar HD, Sloan JA. Screening for lung cancer: Mayo Clinic study with low-dose spiral CT scan (SCT) and sputum cytology (prevalence screen). Presented at 2000 ALA/ATS International Conference; Toronto, Ontario, Canada, May 5-10, 2000.

126. Mandrekar J, Sargent DJ, Novotny PJ, Sloan JA. A general Gibbs Sampling algorithm for

analyzing linear models using the SAS system. Presented at MWSUG ‘99 (Midwest SAS Users Group) 10th Anniversary Conference; Columbus, OH; September 26-28, 1999.

125. Sloan J, Croghan I, Croghan G, Hurt R, Patten C, Loprinzi C, Novotny P, Dekrey W,

Mailliard J, Ebert L. Validation of the Health Status Questionnaire for Assessing Smokers Who are Trying to Quit. Society of Behavorial Medicine. Rapid Communication, San Diego, CA; March 1999.

124. Croghan GA, Hurt RD, Croghan IT, Sloan J, Novotny P, Loprinzi C, DeKrey MN, Foster

MA. Comparison of a 15 mg transdermal nicotine patch alone versus nicotine nasal spray alone versus both for smoking cessation. J Addictive Diseases 17(4):121, 1998, Presented at ASAM in November 1998.

123. Patten CA, Croghan GA, Hurt RD, Croghan IT, Sloan J, Novotny P, Loprinzi C, DeKrey

MN, Foster MA. Relationship of alcoholism and depression to smoking abstinence rates with transdermal nicotine patch versus nicotine nasal spray versus both for smoking cessation. Presented at ASAM in November 1998. J Addictive Diseases 17(4):130, 1998.

122. Burke K, O’Rourke D, Sloan JA. Individualizing nighttime care for residents in a personal

care setting. Presented at the 10th Annual Canadian Gerontological Nurse Association, Edmonton; May 28, 1999.

28

Sloan CV, 5/7/2008

121. Sloan JA. Challenges in Gathering and Analyzing Quality of Life Data in Health Care Research. Presented at the Statistical Society of Canada, University of Regina; June 8, 1999.

120. Sloan JA, Cha SS, Wagner JL, Albert SR, Lindman J, Allmer C. Analyzing oncology

patient health care costs using the SAS system. SUGI 24; Miami Beach, FL; April 11-14, 1999.

119. Mandrekar J, Sargent DJ, Novotny PJ, Sloan JA. A general Gibbs sampling algorithm for

analyzing linear models using the SAS system. SUGI 24; Miami Beach, FL; April 11-14, 1999.

118. Quella SK, Loprinzi CL, Barton D, Knost JA, Sloan J, Gerstner JB, LaVasseur B, Swan D,

Krupp KR, Miller KD, Novotny P. Evaluation of soy phytoestrogens for treatment of hot flashes in breast cancer survivors: A NCCTG trial. Presented at the American Society of Clinical Oncology; Atlanta, GA; May 15-18, 1999.

117. Zahasky KM, Loprinzi CL, Sloan J, Novotny PJ, Quella SK. Detailed prospective data

regarding tamoxifen-associated hot flashes. Presented at the American Society of Clinical Oncology; Atlanta, GA; May 15-18, 1999.

116. Colon-Otero G, Krook JE, Windschitl HE, Niedringhaus RD, Al-Khatib HS, Marks RS,

Hillman S, Sloan J. A Phase II trial of Edatrexate (E), Vinblastine (V), Adriamycin (A), Cisplatin (C) and Filgrastim (EVAC-GCSF) in patients with advanced non-small cell lung carcinomas: A North Central Cancer Treatment Group (NCCTG) Study. Presented at the American Society of Clinical Oncology; Atlanta, GA; May 15-18, 1999.

115. Marks RS, Sloan JA, Hillman SL, Krook J, Kugler J, Mailliard J, Hatfield A, Knowlton L,

Jett J. Empirically based evidence for determination of stratification factors and interpretation of toxicity profiles: A patient-level meta-analysis of North Central Cancer Treatment Group (NCCTG) and Mayo Clinic Lung Cancer Clinical Trials. Presented at the American Society of Clinical Oncology; Atlanta, GA; May 15-18, 1999.

114. Bonner JA, Sloan JA, Hillman SH, Shanahan TG, Brooks BJ, Marks RS. A quality-

adjusted re-analysis of a Phase III trial comparing once-daily thoracic radiation therapy versus twice-daily thoracic radiation therapy in patients with limited stage small cell lung cancer. Presented at the American Society of Clinical Oncology; Atlanta, GA; May 15-18, 1999.

113. Anderson P, Clawson M, Wylam M, Arndt C, Smithson W, Markovic N, Burch P, Gornet

M, Sloan JA. Aerosol GM-CSF: A low toxicity, lung specific biologic therapy in patients with lung metastases. Presented at the American Society of Clinical Oncology; Atlanta, GA; May 15-18, 1999.

112. Sloan JA, Sargent DJ, Atherton Skaff P, Allmer C, Loprinzi CL. A simple approach for

defining clinically relevant effects in quality of life measures. Presented at the American Society of Clinical Oncology; Atlanta, GA; May 15-18, 1999.

111. Alberts S, Goldberg RM, Fonseca R, Erlichman C, Sloan J, Kaufmann SH, Pitot HC,

Rubin J, Adjei A, Burch P, Miller LL and Pharmacia & Upjohn Co., Kalamazoo, MI. Phase I study of CPT-11/5-FU and leucovorin (LV) in advanced cancer. Presented at the American Society of Clinical Oncology; Atlanta, GA; May 15-18, 1999.

29

Sloan CV, 5/7/2008

110. Galanis E, Goldberg R, Erlichman C, Sloan J, Reid J, Pitot H, Rubin J, Alberts S, Adjei A, Burch P, Safgren S, Atherton-Skaff P, Witzig T, Ames M. Phase I trial of sequential administration of Tomudex and 5-Iodo-2’-Deoxyuridine (IdUrd). Presented at the American Society of Clinical Oncology; Atlanta, GA; May 15-18, 1999.

109. Erlichman C, Adjei A, Sloan J, Pitot H, Goldberg R, Peethambaram P, Alberts S, Galanis

E, Hanson L, Reid J, Rubin J, Burch P, Thornton D, Walling J, and Eli Lilly and Company, Indianapolis, Indiana. A Phase I trial of MTA (Multitargeted antifoate, LY231514) and Gemcitabine (Gemzar) in patients with locally advanced or metastatic cancer. Presented at the American Society of Clinical Oncology; Atlanta, GA; May 15-18, 1999.

108. Adjei AA, Erlichman C, Davis JN, Reid J, Sloan J, Statkevich P, Zhu Y, Marks RS, Pitot

HC, Goldberg R, Hanson L, Alberts S, Cutler D, Kaufmann SH, Schering-Plough Research Institute, Kenilworth, NJ. A Phase I and pharmacologic study of the Farnesyl Protein Transferase (FPT) inhibitor SCH 66336 in patients with locally advanced or metastatic cancer. Presented at the American Society of Clinical Oncology; Atlanta, GA; May 15-18, 1999.

107. Atherton Skaff P, Sloan J, Anderson R, Reid J, Rahman E, Erlichman C. An integrated

system for monitoring, reporting, and analyzing Phase I oncology clinical trials. Presented at Society for Clinical Trials; Anaheim, CA;’ May 2-5, 1999.

106. Sloan J, Sargent D, Lindman J, Allmer C, Atherton Skaff P, Zhang L, Hillman S, Creagan

E. A new graphic for quality-adjusted life years (QALY) survival analysis: The QALY Plot. Presented at Society for Clinical Trials; Anaheim, CA; May 2-5, 1999.

105. Niland JC, Stahl DC, Jimenez A, Cole S, Miller S, Yip R, Carroll B, Wien M, Roden S,

Bellin M, Rickard K. Web-based systems for protocol document management. Presented at Society for Clinical Trials; Anaheim, CA; May 2-5, 1999.

104. Sloan JA, Atherton Skaff P, Reid J, Pitot H, Erlichman C, Schaaf L. Limited sampling

models for Irinotecan pharmacokinetics. Presented at the American Society for Clinical Pharmacology and Therapeutics; San Antonio, TX; March 18-21, 1999.

103. Sloan JA, Sargent DJ. When less is more: The role of single-item overall QOL linear

analogue self-assessment (LASA) measures in clinical research. Presented at the 5th Annual Conference of the International Society for Quality of Life Research; November 15-18, 1998.

102. Sloan JA, Sargent DJ, Allmer C, Atherton Skaff P, Zhang L, Creagan ET. A new graphic

for quality-adjusted life years (QALY) survival analysis: The QALY Plot. Presented at the 5th Annual Conference of the International Society for Quality of Life Research; November 15-18, 1998.

101. Sloan JA. The search for clinically relevant effects in QOL. Presented at the 5th Annual

Conference of the International Society for Quality of Life Research; November 15-18, 1998.

99. Sloan J. Measuring quality of life and nutritional status: Approaches and challenges.

Presented at The Annual Fall Conference of the Minnesota Chapter of ASPEN, October 3, 1998.

98. Sloan J. Massage therapy in palliative care. Presented at the 8th Annual Provincial

30

Sloan CV, 5/7/2008

Hospice/Palliative Care Conference; Winnipeg, Manitoba, Canada; September 25, 1998. 97. Alberts S, Wagner J, Sloan J, VanGrevenhof P, Killian J, Lindman J, Chute C, O’Connell

M, Cha S. Incremental costs of enrolling in cancer clinical trials: A population-based analysis. Presented at the ASHR Annual Meeting;Washington, DC; June 15, 1998.

96. Rayson D, Pitot HC, Reid JM, Ames MM, Bagniewski PG, Erlichman C, Sloan JA, Adjei

AA. A Phase I study of bizelesin (NSC 615291) in solid tumors. Presented at the 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy; Amsterdam, The Netherlands; June 16-19, 1998.

95. Sloan JA, Loprinzi CL, Laurie J, Novotny P, Krook J, Vukov A, Maksymiuk A, Wiesenfeld

M, Schaefer P, Kardinal C, Hatfield A, Tschetter L. A simple stratification factor prognostic for survival in advanced cancer: The GBU Index. Presented at ASCO; Los Angeles, CA; ASCO Proceedings 17:2136, 1998.

94. Anderson PM, Wiseman GA, Sloan JA, Hartmann LC, Arndt CAS. 153Samarium-EDTMP

therapy for osteoblastic bone metastases and osteosarcoma: A dose escalation trial with stem cell support. ASCO Proceedings 17:2076, 1998.

93. Geoffroy FJ, Perez EA, Durazo-Arvizu R, Farr GH, Tazelaar HD, Hatfield AK, Marks RS,

Sloan J, Mailliard JA, Krook JE, Levitt R. Phase II study of oral etoposide and intravenous (IV) paclitaxel in extensive small cell lung cancer (SCLC): A North Central Cancer Treatment Group. Presented at ASCO; Los Angeles, CA; ASCO Proceedings 17:1824, 1998.

92. Bonner JA, Shanahan TG, Brooks BJ, Marks RS, Sloan JA. Phase III comparison of

once-daily thoracic radiation versus twice-daily thoracic radiation in patients with limited stage small cell lung cancer. Presented at ASCO; Los Angeles, CA; ASCO Proceedings 17:1756, 1998.

91. Erlichman C, Adjei A, Alberts S, Sloan J, Goldberg R, Pitot H, Rubin J. Phase I study of

Bay 12-9566-A Matrix metalloproteinase inhibitor (MMPI). Presented at ASCO; Los Angeles, CA; ASCO Proceedings 17:837, 1998.

90. Fonseca R. Goldberg RM, Erlichman C, Sloan JA, Kaufmann SH, Miller LL. Phase I

study of the combination of CPT-11/5-FU and leucovorin (LV). Presented at ASCO; Los Angeles, CA; ASCO Proceedings 17:781, 1998.

89. Okuno SH, Woodhouse CL, Loprinzi CL, Sloan JA, Axvig C, Tirona MT, Clemens-

Schutjer D, Michalak J, Pierson N, LaVasseur BI, Swan D, Ebbert L. Phase III placebo-controlled clinical trial evaluation of Glutamine for decreasing mucositis in patients receiving 5FU (fluorouracil)-based chemotherapy. ASCO Proceedings 17:256, 1998.

88. Martenson JA, Bollinger JW, Sloan JA, Urias RE, Dick SJ, Gagnon JD, Longo JM, Moore

RL. Sucralfate does not prevent bowel toxicity during pelvic radiation therapy: Results of a randomized North Central Cancer Treatment Group study. ASCO Proceedings 17:249, 1998.

87. Kugler J, Loprinzi CL, Schaefer P, Sloan JA, Michalak J, Stella P, Levitt R, Quella S,

Tschetter L, Windschitl H, Novotny P. ASCO Proceedings 17:239, 1998. 86. Hammack J, Michalak J, Loprinzi C, Sloan J, Soori G, Maksymiuk A, Rowland K, Stella P,

31

Sloan CV, 5/7/2008

Johnson J. A phase III study of nortriptyline for alleviation of painful paresthesiae due to cis-platinum (CDDP)-induced peripheral neuropathy (NCCTG study 93-92-52). ASCO Proceedings 17:229, 1998.

84. Constantinou CL, Loprinzi CL, Sloan JA. A survey of oncologists, surgeons and allied

health staff regarding the delivery of prognosis to the cancer patient. ASCO Proceedings 17:215, 1998.

84. Loprinzi CL, Pisansky TM, Fonseca R, Sloan JA, Zahasky KM, Quella SK, Rummans TA,

Dumesic DA, Perez EA, Novotny PJ. Venlafaxine-associated hot flash reduction in cancer survivors. Presented at ASCO; Los Angeles, CA; ASCO Proceedings 17:170, 1998.

83. Kaufmann S, Letendre L, Litzow M, Reed J, Hanson C, Sloan J. Phase I study of

continuous infusion (CI) Topotecan (TPT) and carboplatin (CBDCA) for relapsed or refractory acute leukemia (AL). ASCO Proceedings 17:107, 1998

82. Bonner JA, Marks RS, Sloan J, Brindal J. Comparison of toxicities of twice-daily thoracic

irradiation alone vs. the same thoracic irradiation with either bolus etoposide/cisplatin or daily etoposide/cisplatin in patients with locally advanced non small cell lung cancer. Presented at American Radium Society; San Francisco, CA; March 30, 1998.

81. Adjei AA, Kaufmann SH, Reid J, Sloan JA, Alberts SR, Goldberg RM, Erlichman C. A

phase I study of pyrazoloacridine (PZA) and carboplatin (CBDCA) in patients with advanced solid tumors. Presented at AACR; New Orleans, LA; March 30, 1998.

80. Galanis E, Goldberg RM, Erlichman C, Rubin J, Pitot HC, Adjei AA, Alberts SR, Burch PA,

Reid JM, Safgren SL, Witzig TE, Sloan JA, Ames MM. Phase I trial of sequential administration of Tomudex and 5-lodo-2’-Deoxyuridine (IdUrd). Presented at AACR; New Orleans, LA; March 30, 1998. (Received the Glaxo-Wellcome Oncology Clinical Research Award.)

79. Sloan JA, Sargent DJ, Allmer C, Zhang L. A new graphic for quality-adjusted life years

(QALY) survival analysis: the QALY plot. DIA-QOL evaluation. Hilton Head, SC; April 7, 1998.

78. Bonner JA, Marks RS, Sloan J, Brindle J. Comparison of toxicities of twice-daily thoracic

irradiation alone vs. the same thoracic irradiation with either bolus etoposide/cisplatin or daily etoposide/cisplatin in patients with locally advanced non-small cell lung cancer. New Orleans, LA; March 30, 1998.

77. Sloan JA. Searching for clinically relevant effects in QOL instruments. DIA-QOL

evaluation; Hilton Head, SC; April 6, 1998. 76. Atherton Skaff P, Sloan JA. Design and analysis of equivalence trials using the SAS

system. SUGI 23; Nashville, TN; March 23, 1998. 75. Sloan JA, Novotny PJ, Loprinzi CL. Analyzing quality of life data via the SAS system.

Invited presentation, SUGI 23; Nashville, TN; March 23, 1998. 72. Sloan JA, Loprinzi CL, Laurie J, Novotny P, Krook J, Krugler J, Maksymiak A, Weisenfeld

M, Schactter P, Kardinal K, Hatfield A, Tschelter C. A simple stratification factor prognostic for survival in advanced cancer: the GBU index. Submitted for ASCO 1998.

32

Sloan CV, 5/7/2008

73. Rummans TA, Bretscher M, Sloan JA, Frost M, Bartlett A, Borkenhagen L, Kaur JS,

Loprinzi CL. Quality of life in hospice patients and their caregivers: a longitudinal descriptive study. Academy of Psychosomatic Medicine; Coronado; November 20, 1997. (Best poster award.)

72. Sloan JA, O’Fallon JR, Suman VJ, Sargent DJ. Incorporating quality of life measurement

into oncology clinical trials. Invited talk for the International Society for Quality of Life research; Vienna, Austria; November 5, 1997.

71. Bonner JA, Frytak S, Sloan J, Foote RL, Marks RS, Creagan ET, Richardson RL,

Deschamps C. Daily etoposide and cisplatin during thoracic radiotherapy for patients with locally advanced non-small cell lung cancer. ASTRO; October 23,1997.

70. Sloan JA, Bonner JA, McGinnis WL, Stella P, Marks R. Smoking habits of patients with

newly diagnosed stage IIIA.IIIB non-small cell lung cancer. ASTRO October 23,1997. 69. Bagniewski PG, Reid JM, Pitot HC, Sloan JA, Ames MM. Pharmacokinetics of Dolastatin

10 in adult patients with solid tumors. AACR 38:1492, 1997. 68. Fonseca R, Goldberg RM, Erlichman C, Kaufmann SH, Sloan JA, and Miller LL. Phase I

study of CPT-11/5-FU/leucovorin. AACR 38:513, 1997. 67. Sloan JA, Novotny P, Loprinzi CL. Development of a prognostic index for patients with

advanced cancer. Mayo HSR seminar series; October 6, 1997. 66. Sloan JA, Bretscher M, Rummans T. Measuring quality of life (QOL) in hospice patients:

methodological issues and results of a longitudinal descriptive study. 6th Annual Provincial Hospice/Palliative Care Conference; Winnipeg, Manitoba; September 26-27, 1997.

65. Sloan JA. The problem of quality of life in medicine. Mayo Outcomes Research Group

seminar series; Sept. 29, 1997. 64. Sloan JA, O’Fallon JR, Suman VJ, Sargent DJ. Incorporating quality of life measurement

into oncology clinical trials. Joint Statistical Meetings ASA/IMS; Anaheim, CA; August 14, 1997.

63. Sloan JA. Two examples from a statistical consulting practice: Crossover trials analysis

and phase II trial design. Eli Lilly, Inc.; Indianapolis, IN; July 23, 1997. 62. Sargent DJ, Sloan JA, Cha S. Sample size and design considerations for phase II clinical

trials with correlated observations. Society for Clinical Trials; Boston, MA; July 9, 1997. 61. Bretscher M, Sloan JA, Rummans T. Quality of Life in Hospice Patients: A Longitudinal

Descriptive Study. American Academy of Hospice and Palliative Medicine; Chicago, IL; June 26-28, 1997.

59. Bretscher M, Sloan JA, Rummans T. Quality of Life in Hospice Patients: Relationship

Between Patient, Caregiver, and Hospice Staff Assessment. American Academy of Hospice and Palliative Medicine; Chicago, IL; June 26-28, 1997.

59. Bretscher M, Sloan JA, Rummans T. Quality of Life in Caregivers of Hospice Patients: A

33

Sloan CV, 5/7/2008

Longitudinal Descriptive Study. American Academy of Hospice and Palliative Medicine; Chicago, IL; June 26-28, 1997.

58. Sloan JA, Nemecek AM, Blood P, Scott-Findlay S, Trylinski C, Whittaker H, El Sayed S,

Clinch J, Khoo K. The Trajectory of Cancer Patients Through the Manitoba Health Care System. The Department of Laboratory Medicine/Pathology and The Mayo Cancer Center Research Symposium; May 20, 1997.

57. Alberts SR, Erlichman C, Reid JM, Ames MM, Sloan JA, Richardson RL, Goldberg RM.

Phase I study of the synthetic duocarmycin derivative KW2189 given daily for five days every six weeks. ASCO Proceedings; 16:748, 1997.

56. Arndt C, Womer R, Sloan J, Hawkins D, Miser J. Alternating cycles of vincristine,

doxorubicin, cyclophosphamide (VDC) and etoposide/ifosfamide (EI) for treatment of nonmetastatic rhabdomyosarcoma and undifferentiated sarcomas (US) of childhood. ASCO Proceedings; 16:1835, 1997.

55. Barton D, Loprinzi CL, Veeder M, Sloan J, Fidler P, Egner J, Stella P, Quella S, Swan D,

Vaught N, Novotny P. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. ASCO Proceedings; 16:164, 1997.

54. Kaur JS, Roubidoux M, Sloan J, Lobell M. Clinical and mammographic correlates of

breast disease in Sioux women. ASCO Proceedings; 16:472, 1997. 53. Loprinzi CL, Kugler J, Sloan J, Mailliard J, Krook J, Wilwerding M, Rowland K, Camoriano

J. Phase III randomized comparison of megestrol acetate, dexamethasone, and fluoxymesterone for the treatment of cancer anorexia/cachexia. ASCO Proceedings; 16:167, 1997.

52. McElroy EA, Pitot HC, Erlichman C, Reid JM, Ames MM, Windebank AJ, Sloan JA, Rubin

J. Phase I trial of dolastatin-10 in patients with advanced solid tumors. ASCO Proceedings; 16:782, 1997.

51. Nair S, Marschke R, Grill J, Sloan J, Tazelaar H, Drevyanko T, Michalak J, Marks R. A

phase II study of paclitaxel (Taxol¨) and cisplatin (CDDP) in the treatment of extensive stage small cell lung cancer (ESSCLC). ASCO Proceedings; 16:1629, 1997.

50. Quella S, Loprinzi CL, Sloan J, Vaught N, DeKrey W, Fischer T, Fink G, Pierson N,

Pisansky T. Long-term use of megestrol acetate for the treatment of hot flashes in cancer survivors. ASCO Proceedings; 16:278, 1997.

49. Sloan JA, Nemecek AM, Blood P, Scott-Findlay S, Trylinski C, Whittaker H, El-Sayed S,

Clinch J, Khoo K. The trajectory of cancer patients through the Manitoba health care system. ASCO Proceedings; 16:1531, 1997.

48. Wiesenfeld M, Marks R, Grill J, Sloan J, Tazelaar H, Carroll T, Kugler J, Krook J. A

randomized phase II study of topotecan (TOPA) and cisplatin (CDDP) with Filgrastim (G-CSF) versus topotecan and paclitaxel (Taxol) with filgrastim in patients with advanced non-small cell lung cancer. ASCO Proceedings; 16:1755, 1997.

47. Sloan JA. Quality of life measurement: theory and clinical realities. Invited lecture for

Mayo HSR outcomes research course; May 15, 1997.

34

Sloan CV, 5/7/2008

46. Sloan J. Alternative Designs for Phase I Clinical Trials. Oncology Core Curriculum Lecture Series, Rochester, April 1, 1997.

45. Sloan J, Novotny P, Loprinzi CL, Ghosh M. Graphical and Analytical Tools for Two-Period

Crossover Clinical Trials. Presented at the 22nd Annual SUGI Meeting; San Diego, CA; March 18, 1997. (Best contributed paper award).

44. Pitot HC, Ames MM, Erlichman C, Reid JM, Windebank AJ, Sloan JA. Analysis of a

Phase I clinical protocol: Phase I trial of dolastatin-10 in patients with advanced cancer. Current Topics in Tumor Biology Journal Club (Rochester, MN); February 26, 1997.

43. Sloan J. The lived experience of patients with long term type I diabetes. Endocrinology

Journal Club; Rochester, MN: February 20, 1997. 42. Sloan J. Incorporating quality of life measurement into oncology clinical trials. Presented

at HSR Seminar Series; Rochester, MN; January 20, 1997. 41. Kristjanson LJ, Sloan JA, Dudgeon D, Adaskin E. Predictors of family functioning and

family members’ health in palliative cancer care. University of Manitoba, Faculty of Medicine Oncology Grand Rounds; Winnipeg, Manitoba, Canada; November 12, 1996.

40. Alberts SR. Erlichman C, Reid JM, Ames MM, Sloan JA, Richardson RL. Phase I trial of

KW2189 in solid tumors using a 5–day administration schedule. AACR Proceedings; 37:A2682, 1996.

39. Bagniewski PG, R Reid JM, Ames MM, Bonner JA, Buckner JC, Sloan JA. Increased

etoposide clearance in patients with glioma may be associated with concurrent glucocorticoid or anticonvulsant treatment. AACR Proceedings; 37:A1224, 1996.

38. Goldberg RM, Reid JM, Ames MM, Sloan JA, Rubin J, Erlichman C, Kuffel MJ, Fitch TR.

Phase I clinical trial and pharmacokinetics of Fazarabine. AACR Proceedings; 37:1127, 1996.

37. McGinnis WL, Loprinzi CL, Buskirk SJ, Sloan JA, Novotny PJ, Drummond RG, Frank AR,

Shanahan TG. Phase III evaluation of sucralfate for radiation-induced esophagitis. ASTRO; October, 1996.

36. Sloan J. Quality of Life Assessment, Mayo Cancer Center Medical Oncology Grand

Rounds; September 13, 1996. 35. Sloan JA, Yeung ASK. Alternatives for a reformulation of Cronbach’s alpha coefficient.

ASA, Chicago, IL; August 4-8, 1996. 34. Perez EA, Loprinzi CL, Sloan J, Owens DT, Novotny P, Bonner J. Utility of follow-up

testing procedures in small cell lung cancer patients who are clinically disease free following therapy. ASCO Proceedings; 15:930, 1996.

32. Foote RL, Loprinzi CL, Gulavita S, Sloan J, Earle J, Burk M, Novotny P, Frank AR.

Randomized trial of a nonabsorbable antibiotic lozenge for alleviation of radiation-induced mucositis. ASCO Proceedings; 15:1728, 1996.

32. Ghosh C, Loprinzi CL, Camoriano J, Sloan J, Steen P, Michalak J, Schaefer P, Gerstner

J, White D, Hatfield A, Quella S. Evaluation of sucralfate for alleviating 5FU-induced

35

Sloan CV, 5/7/2008

stomatitis. ASCO Proceedings; 15:1729, 1996. 31. Ellison N, Loprinzi CL, Kugler J, Hatfield A, Miser A, Sloan J, Wender D, Rowland K,

Molina R, Cascino T, Vukov A, Dhaliwal H, Ghosh C. Evaluation of a capsaicin cream for the treatment of postoperative neuropathic pain. ASCO Proceedings; 15:1730, 1996.

30. Law M, Loprinzi CL, Veeder M, Rowland K, vanHaelst-Pisani C, Abu-Ghazaleh S, Sloan

J, Windschitl H, Kaur J, Ellison N. Double-blind cross-over trial of replens versus KY jelly for treating vaginal dryness and dyspareunia in breast cancer survivors. ASCO Proceedings; 15:1731, 1996.

29. Sloan J, Loprinzi CL, O’Fallon JR, Kuross SA, Miser AW, Mahoney MR, Heid IM. A

randomized comparison of four quality of life (QOL) tools in patients with advanced cancer. ASCO Proceedings; 15:1632, 1996.

28. Heid I, Sloan J. Personnel profiles by gender, modeled for 1996-2015. SUGI 21;

Chicago, IL; March 7-10, 1996. 27. Sloan J, Nemecek A. Measurement issues in constructing cancer patient histories.

155th annual meeting of the American Statistical Association; Orlando, FL; August 17, 1995.

26. Sloan J. Teaching nurses biostatistics using a project-oriented approach, presented at

the 155th annual meeting of the American Statistical Association; Orlando, FL; August 15, 1995.

24. Blood P, Sloan J, Nemecek A. The cancer patients journey through the Manitoba health

care system. 10th anniversary community cancer programs network symposium; Winnipeg, Manitoba, Canada; June 1, 1995.

24. Sloan J. Considerations in the design and analysis of a clinical research protocol.

Workshop in cooperation with Clinical Research Consultants, Inc.; November 15, 1994. 23. Sloan J, Paterson B. The lived experience of individuals with long term type I diabetes:

identifying self-care decision-making processes for disease management. Presented at the International Nursing Research Conference; Vancouver, British Columbia, Canada; May 4-8, 1994

22. Sloan J. Using SAS to carry out a more complete analysis of paired comparisons data

via Thurstone scaling. 19th International SUGI Conference; Dallas, TX; April 9- 12, 1994. 21. Sloan J. Using SAS to carry out Coombs unidimensional unfolding analysis for paired

comparisons data.19th International SUGI Conference; Dallas, TX; April 9- 12, 1994.

20. Sloan J, Paterson B. I know my body: identifying self-care decision-making processes for disease management (Preliminary Findings). Diabetes Educators Section of the Canadian Diabetes Association annual meeting; Banff, Alberta, Canada; September 29, 1993.

19. Sloan J. Towards a more intelligent use of Cronbach’s alpha coefficient. Department of

Mathematics and Statistics, Simon Fraser University; Vancouver, British Columbia, Canada; August 11, 1993.

36

Sloan CV, 5/7/2008

18. Sloan J. Designing health care surveys. Presented to the School of Nursing, UBC; Vancouver, British Columbia, Canada; August 9, 1993.

17. Sloan J. Questionnaire development: special considerations for health care surveys.

Clinically Based Research: Issues in Primary Health Care Delivery, Health Promotion and Health Care Economics; Winnipeg, Manitoba, Canada; November 14, 1992.

16. Sloan J. Measuring patient preferences in cancer treatment: an example of Coombs

unfolding model. Statistical Association of Manitoba; Winnipeg, Canada; May 1992. 15. Nemecek A, Trylinski C, Sloan J. The challenge of ensuring satisfaction. Canadian

Association of Psychosocial Oncology; Kingston, Ontario, Canada; May 9, 1992. 14. Sloan J. Control preferences for treatment decision making in cancer patients. Miles

Pharmaceuticals Inc.; Berkeley, CA; March 1992. 13. Sloan J. A nonrandom sampling of nursing research.Bristol-Myers-Squibb

Pharmaceuticals, Inc.; Wallingford, CT; February 1992. 11. Sloan J. Bayesian predictive intervals for mixture distributions. Department of Statistics,

University of Regina; Saskatchewan, Canada; July 1991. 11. Sloan J. How to lie with statistics. Manitoba Nursing Research Institute Research

Seminar; Winnipeg, Manitoba, Canada; February 1991. 10. Sloan J. Evaluation of statistical consultation for nursing research. Annual meeting of the

MARN; Winnipeg, Manitoba, Canada; September 1990. 9. Sloan J. Questionnaire Design for Health Care Research. Workshop presented to the

Manitoba Association of Quality Assurance Managers; Winnipeg, Manitoba, Canada; June 1990.

8. Sloan J, Degner, L. Developing the research process for cancer research. Manitoba

Cancer Outreach Conference; Wasagaming, Manitoba, Canada; March 12, 1990. 7. Sloan J. On the distribution and testing of Cronbach’s alpha coefficient. Department of

Biostatistics, University of Toronto;Toronto, Ontario, Canada; December 1988. 6. Sloan J. Using Chernoff faces to represent multivariate data in nursing research,

Computers in Medicine Congress; Niryghyhaza, Hungary; September 1988. 5. Sloan J, Schwarz C, Neden L. Case studies in data analysis. Annual meeting of the

Statistical Society of Canada; Victoria, British Columbia, Canada; June 1988. 4. Sloan J. Can you give me some stats? Miscommunication of statistical results in the

media. Annual conference of the International Association of Business Communicators; September 13, 1988.

3. Sloan J. Using the SPSS/PC+ package for health care research. Workshop presented at

the St. Boniface General Hospital Nursing Research Center; Winnipeg, Manitoba, Canada; January 1988.

2. Sloan J. Designing an intervention study to assess stomatitis. Terry Fox workshop on

37

Sloan CV, 5/7/2008

stomatitis. Vancouver, British Columbia, Canada; December 1987. 1. Sloan J. Novel graphical presentations for multivariate data. Annual meeting of the

Statistical Association of Manitoba; Winnipeg, Manitoba, Canada; May 1987. 12. VISITING PROFESSORSHIPS 13. CLINICAL PRACTICE, INTERESTS, AND ACCOMPLISHMENTS 14. RESEARCH INTERESTS 15. RESEARCH GRANTS AWARDED

Principal Investigator. A Bayesian reformulation of Cronbach’s alpha coefficient. National Science and Engineering Research Council (NSERC), 1994-1997, $10,000 per annum, plus $17,702 equipment grant for SPARC20 computing station. (This grant is the Canadian equivalent of an R01.) Co-investigator (Principal investigator Donna Goodridge, R.N.,M.N.) Prevention strategies, treatment, trajectory and related costs of pressure ulcers in four Manitoba health care facilities. Manitoba Health Organization 1994-1996, ($29,000). (Best Manitoba nursing research project award 1995/96.)

16. PATENTS 17. BIBLIOGRAPHY

a. Refereed Journal 243. Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, Tan AD,

Atherton PJ, Sloan JA, Tefferi A. The burden of fatigue and quality of life in myeloproliferative Disorders (MPDs). Cancer 2007;109:68-76.

242. Huschka MM, Mandrekar SJ, Schaefer PL, Jett JR, Sloan JA. A pooled analysis of

quality of life measures and adverse events data in North Central Cancer Treatment Group lung cancer clinical trials. Cancer 2007;109:787-795.

241. Croghan IT, Hurt RD, Dakhil SR, Croghan GA, Sloan JA, Novotny PJ, Rowland KM,

Bernath A, Loots ML, Le-Lindquister NA, Tschetter LK, Garneau SC, Flynn KA, Ebbert LP, Wender DB, Loprinzi CL. Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention. Mayo Clin Proc 2007 Feb: 82:2):186-195.

240. Thomas MR, Dyrbye LN, Huntingon JL, Lawson KL, Novotny PJ, Sloan JA, Shanafelt

TD. How do distress and well-being relate to medical student empathy? A multicenter study. Soc Gen Intern Med. 2007;22:177-183.

239. Alberts SR, Nobotny PJ, Sloan JA, Danella J, Bostwick DG, Sebo TJ, Blute ML, Fitch

TR, Levitt R, Lieverman R, Loprinzi CL. Flutamide in men with prostatic intraepithelial

38

Sloan CV, 5/7/2008

neoplasia: a randomized, placebo-controlled chemoprevention trial. Am J Ther 2006;13(4):291-297.

238. Sloan JA, Frost MH, Berzon R, Dueck A, Guyatt G, Moinpour C, Sprangers M, Ferrans C, Cella D, Clinical Significance Consensensus Meeting Group. The clinical significance of quality of life assessments in oncology: a summary for clinicians. Support Care Cancer. 2006;14:988-998.

237. Barton DL, Loprinzi C, Atherton PJ, Kottschade L, Collins M, Carpenter P, Adjei A,

Rummans TA, Shanafelt T, Christensen B, Sloan J. Dehydroepiandrosterone for the treatment of hot flashes: A pilot study. Supportive Cancer Therapy 2006; 3(2):91-7.

236. Atherton PJ, Sloan JA. Rising importance of patient-reported outcomes. Lancet

Oncology 2006; 7(11):883-4. 235. Loprinzi CL, Barton DL, Sloan JA. Whose Opinion Counts? Journal of Clinical

Oncology 2006; 24(33): 5183-5185. 234. Dyrbye LN, Thomas MR, Huschka MM, Lawson KL, Novotny PJ, Sloan JA, Shanafelt

TD. A multicenter study of burnout, depression, and quality of life in minority and nonminority US medical students. Mayo Clin Proc 2006; 81(11):1435-42.

233. Callstrom MR, Atwell TD, Charboneau JW, Farrell MA, Goetz MP, Rubin J, Sloan JA,

Novotny PJ, Welch TJ, Maus TP, Wong GY, Brown KJ. Painful metastases involving bone: Percutaneous image-guided cryoablation - Prospective trial interim analysis. Radiology 2006; 241(2):572-80.

232. Lapid MI, Rummans TA, Brown PD, Frost MH, Johnson ME, Huschka MM, Sloan JA,

Richardson JW, Hanson JM, Clark MM. Improving the quality of life of geriatric cancer patients with a structured multidisciplinary intervention: a randomized controlled trial. Accepted at Palliative & Supportive Care Journal, 2006.

231. Kung S, Rummans TA, Colligan RC, Clark MM, Sloan JA, Novotny PJ, Huntington JL.

Association of Optimism-Pessimism with Quality of Life Patients with Head and Neck and Thyroid Cancers. Mayo Clinic Proceedings 2006; 81(12): 1545-1552.

230. Revicki DA, Cella D, Hays RD, Sloan JA, Lenderking WR, Aaronson NK.

Responsiveness and minimal important differences for patient reported outcomes - art. no. 70. Health & Quality of Life Outcomes 2006 Sep 27; 4:70.

229. Barton DL, Loprinizi C, Jatoi A, Vincent A, Limburg P, Bauer B, Sood A, Good M,

Bearden III JD, Kelaghan J, Sloan J. Can Complemetary and Alternative Medicine Clinical Cancer Research Be Successsfully Accomplished? The May Clinic-North Central Treatment Group Experience. Journal of the Society for Integrative Oncology 2006; 4(4): 143-152.

228. Pitot HC, Adjei AA, Reid JM, Sloan JA, Atherton PJ, Rubin J, Alberts SR, Duncan BA,

Denis L, Schaaf LJ, Yin DH, Sharma A, McGovren P, Miller LL, Erlichman C. A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors. Cancer Chemother Pharmacol 2006; 58(2):165-72.

39

Sloan CV, 5/7/2008

227. Dy GK, Suri A, Reid JM, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Atherton PJ, Hanson LJ, Burch PA, Rubin J, Erlichman C, Adjei AA. A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors. Cancer Chemotherapy & Pharmacology 2005; 55(6):522-30.

226. Loprinzi CL, Levitt R, Barton DL, Sloan JA, Atherton PJ, Smith DJ, Dakhil SR, Moore

DF, Krook JE, Rowland KM, Mazurczak MA, Berg AR, Kim GP. Evaluation of shark cartilage in patients with advanced cancer. Cancer 2005; 104(1):176-182.

225. Bible KC, Lensing JL, Nelson SA, Lee YK, Reid JM, Ames MM, Isham CR, Piens J,

Rubin SL, Rubin J, Kaufmann SH, Atherton PJ, Sloan JA, Daiss MK, Adjei AA, Erlichman C. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clinical Cancer Research 2005; 11(16):5935-5941.

224. Kaufmann SH. Karp JE. Letendre L. Kottke TJ. Safgren S. Greer J. Gojo I. Atherton P.

Svingen PA. Loegering DA. Litzow MR. Sloan JA. Reid JM. Ames MM. Adjei AA. Erlichman C. Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia. Clinical Cancer Research 2005; 11(18):6641-9.

223. Galanis E. Okuno SH. Nascimento AG. Lewis BD. Lee RA. Oliveira AM. Sloan JA.

Atherton P. Edmonson JH. Erlichman C. Randlev B. Wang Q. Freeman S. Rubin J. Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Therapy 2005; 12(5):437-45.

222. Baxter NN, Novotny PJ, Jacobson T, Maidl LJ, Sloan JA, Young-Fadok TM. The

Stoma Quality of Life Scale. Disease of the Colon & Rectum 2006; 49(2): 205-12. 221. Bradley EA, Sloan JA, Novotny PJ, Garrity JA, Woog JJ, West SK. Evaluation of The

National Eye Institute Visual Function Questionnaire in Graves’ Ophthalmopathy. Ophthalmology 2006; 113(8):1450-4.

220. West CP, Huschka MM, Novotny PJ, Sloan JA, Kolars JC, Habermann TM, Shanafelt

TD. Association of perceived medical errors with resident distress and empathy - A prospective longitudinal study. JAMA 2006; 296(9):1071-8.

219. Alberts SR, Novotny P, Sloan JA, Danella J, Bostwick DG, Sebo T, Blute ML, Fitch

TR, Levitt R, Lieberman R, Loprinzi CL. Flutamide in men with prostatic intraepithelial neoplasia: a randomized, placebo-controlled chemoprevention trial. American Journal of Therapeutics 2006; 13: 291-7.

218. Sideras K, Schaefer PL, Okuno SH, Sloan JA, Kutteh L, Fitch TR, Dakhil SR, Levitt R,

Alberts SR, Morton RF, Rowland KM, Novotny PJ, Loprinzi CL. Low-molecular-weight heparin in patients with advanced cancer: A phase 3 clinical trial. Mayo Clinic Proceedings 2006; 81(6):758-67.

217. Perez DG, Loprinzi CL, Sloan J, Novotny P, Barton D, Carpenter L, Smith D,

Christensen B, Rummans T. Pilot evaluation of bupriopion for the treatment of hot flashes. Journal of Palliative Medicine 2006; 9(3): 631-7.

216. Clark MM, Rummans TA, Sloan JA, Jensen A, Atherton PJ, Frost MH, Richardson

40

Sloan CV, 5/7/2008

JW, Bostwick JM, Johnson ME, Hanson JM, Brown PD. Quality of Life of Caregivers of Patients with Advanced-Stage Cancer. American Journal of Hospice & Palliative Medicine 2006; 23(3): 185-191.

215. Sloan JA, Frost MH, Berzon R, Dueck A, Guyatt G, Moinpour C, Sprangers M,

Ferrans C, Cella D, Clinical Significance Consensus Meeting Group. The Clinical Significance of Quality of Life Assessments in Oncology: A Summary for Clinicians. Supportive Care Cancer 2006; 14: 988-998.

214. Pockaj BA, Gallagher JG, Loprinzi CL, Stella PJ, Barton DL, Sloan JA, Lavasseur BI,

Rao RM, Fitch TR, Rowland KM, Novotny PJ, Flynn PJ, Richelson E, Fauq AH. Phase III Double-Blind, Randomized, Placebo-Controlled Crossover Trial of Black Cohosh in the Management of Hot Flashes: NCCTG Trial N01CC. Journal of Clinical Oncology 2006; 24(18): 2836-2841.

213. Dueck A, Halyard MY, Frost MH, Sloan JA. Meeting on the FDA Draft Guidance on

Patient-Reported Outcomes. Patient Reported Outcomes Newsletter 2006; 36:1-4. 212. Brown PD, Ballman KV, Rummans TA, Maurer MJ, Sloan JA, Boeve BF, Gupta L,

Tang-Wai DF, Arusell RM, Clark MM, Buckner JC. Prospective study of quality of life in adults with newly diagnosed high-grade gliomas. J Neurooncol 2006; 76(3): 283-91.

211. Dyrbye LN, Thomas MR, Huntington JL, Lawson KL, Novotny PJ, Sloan JA,

Shanafelt TD. Personal life events and medical student burnout: A multicenter study. Acad Med 2006; 81(4): 374-84.

210. Goodridge D, Trepman E, Sloan J, Guse L, Strain LA, McIntyre J, Embil JM. Quality

of Life of Adults with Unhealed and Healed Diabetic Foot Ulcers. Foot & Ankle International 2006; (4): 274-80.

209. Loprinzi CL, Levitt R, Barton D, Sloan JA, Dakhil SR, Nikcevich DA, Bearden III JD,

Mailliard JA, Tschetter LK, Fitch TR, Kugler JW. Phase III Comparison of Depomedroxyprogesterone Acetate to Venlafaxine for Managing Hot Flashes: North Central Cancer Treatment Group Trial N99C7. Journal of Clinical Oncology 2006; 24(9): 1409-1414.

208. Hassan I, Cima RC, Sloan JA. Assessment of Quality of Life Outcomes in the

Treatment of Advanced Colorectal Malignancies. Gastroenterol Clin N Am 2006; 35(1): 53-64.

207. Steensma DP, Molina R, Sloan JA, Nikcevich DA, Schafer PL, Rowland KM,

Dentchev T, Novotny PJ, Tschetter LK, Alberts SR, Hogan TF, Law A, Loprinzi CL. Phase III Study of Two Different Dosing Schedules of Erythropoietin in Anemic Patients with Cancer. Journal of Clinical Oncology 2006; 24(7): 1079-1089.

206. Brown P, Clark MM, Atherton P, Huschka M, Sloan JA, Gamble G, Girardi J, Frost

MH, Piderman K, Rummans TA. Will Improvement in Quality of Life (QOL) Impact Fatigue in Patients Receiving Radiation Therapy for Advanced Cancer? American Journal of Clinical Oncology 2006; 29(1): 52-58.

205. Rummans TA, Clark MM, Sloan JA, Frost MH, Bostwick JM, Atherton PJ, Johnson

ME, Gamble G, Richardson J, Brown P, Martensen J, Miller J, Piderman K, Huschka

41

Sloan CV, 5/7/2008

M, Girardi J, Hanson J. Impacting Quality of Life for Patients with Advanced Cancer with a Structured Multidisciplinary Intervention: A Randomized Controlled Trial. Journal of Clinical Oncology 2006; 24(4): 635-642.

204. Barton DL, Loprinzi C, Atherton, PJ, Kottschade L, Colins M, Carpenter P, Adjei A,

Rummans TA, Shanafelt T, Christensen B, Sloan J. Dehydroepiandrosterone for the Treatment of Hot Flashes: A Pilot Study. Supportive Cancer Therapy 2006: 3(2): 91-97.

203. Sloan JA. Applying QOL Assessments: Solutions for Oncology Clinical Practice and

Research, Part 1. Current Problems in Cancer 2005; 29(6): 271-351. 202. Meyerhardt JA, Sloan JA, Sargent DJ, Goldberg RM, Pollak M, Morton RF,

Ramanathan RK, Williamson SK, Findlay BP, Fuchs CS. Associations between Plasma Insulin-Like Growth Factor Proteins and C-Peptide and Quality of Life in Patients with Metastatic Colorectal Cancer. Cancer Epidemiology, Biomarkers & Prevention 2005; 14(6): 1402-1410.

201. Frost MH, Slezak JM, Tran NV, Williams CI, Johnson JL, Woods JE, Petty PM,

Donohue JH, Grant CS, Sloan JA, Sellers TA, Hartmann LC. Satisfaction after Contralateral Prophylactic Mastectomy: The Significance of Mastectomy Type, Reconstructive Complications, and Body Appearance. Journal of Clinical Oncology 2005; 23(31): 7849-7856.

200. Brown PD, Maurer MJ, Rummans TA, Pollock BE, Ballman KV, Sloan JA, Boeve BF,

Arusell RM, Clark MM, Buckner JC. A Prospective Study of Quality of Life in Adults with Newly Diagnosed High-Grade Gliomas: The Impact of the Extent of Resection on Quality of Life and Survival. Neurosurgery 2005; 57(3): 495-504.

199. Loprinzi CL, Flynn PJ, Carpenter LA, Atherton P, Barton DL, Shanafelt TD, Rummans

TA, Sloan JA, Adjei AA, Mincey BA, Fitch TR, Collins M. Pilot Evaluation of Citalopram for the Treatment of Hot Flashes in Women with Inadequate Benefit from Venlafaxine. Journal of Palliative Medicine 2005; 8(5): 924-930.

198. Kaufmann SH, Karp JE, Letendre L, Kottke TJ, Safgren S, Greer J, Gojo I, Atherton P,

Svingen PA, Loegering DA, Litzow MR, Sloan JA, Reid JM, Ames MM, Adjei AA, Erlichman C. Phase I and pharmacologic study of infusional topotecan and carboplatin in relapsed and refractory acute leukemia. Clinical Cancer Research 2005; 11(18): 6641-6649.

197. Sloan JA, Cella D, Hays RD. Clinical significance of patient-reported questionnaire

data: another step toward consensus. Journal of Clinical Epidemiology 2005; 58: 1217-1279.

196. Molina JR, Reid JM, Erlichman C, Sloan JA, Furth A, Safgren SL< Lathia CD, Alberts

SR. A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin. Anti-Cancer Drugs 2005; 16: 997-1002.

195. Shanafelt TD, West C, Zhao X, Novotny P, Kolars J, Habermann T, Sloan J.

Relationship between increased personal well-being and enhanced empathy among internal medicine residents. JGIM 2005; 559-564.

42

Sloan CV, 5/7/2008

194. Clark MM, Hurt RD, Croghan IT, Patten C, Novotny P, Sloan JA, Shaker RD, Croghan GA, Wos EJ, Rowland KM, Bernath A, Morton RF, Sachdex PT, Tschetter LK, Garneau S, Stella PJ, Ebbert LP, Wender DB, Loprinzi CL. The Prevalence of Weight Concerns in a Smoking Abstinence Clinical Trial. Addictive Behaviors 2006; 31(7): 1144-1152.

193. Sloan JA. QOL SOS: Quality of Life State of the Science: An Editorial Series.

Journal of Cancer Pain & Symptom Palliation 2005; 1(1): 95-98. 192. Wyrwich KW, Bullinger M, Aaronson N, Hays RD, Patrick DL, Symonds T, Sloan JA,

& The Clinical Significance Consensus Meeting Group. Estimating clinically significant differences in quality of life outcomes. Quality of Life Research 2005; 14: 285-295.

191. Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA, Rowland

KM, Alberts SR, Krook JE, Levitt R, Morton RF. Phase III, Randomized, Double-Blind Study of Epoetin Alfa Compared With Placebo in Anemic Patients Receiving Chemotherapy. Journal of Clinical Oncology 2005; 23(12): 2606-2617.

190. Sloan JA. Assessing the Minimally Clinically Significant Difference: Scientific

Considerations, Challenges and Solutions. Journal of Chronic Obstructive Pulmonary Disease 2005; 2: 57-62.

189. Scott-Findlay S, Sloan JA, Nemecek A, Blood P, Trylinski, C, Whittaker H, El Sayed

S, Clinch J, Khoo K. Mapping the journey of cancer patients through the health care system Part 3: An approach to staging. Canadian Oncology Nursing Journal 2005; 4-8.

188. Jatoi A, Kahanic SP, Frytak S, Schaefer P, Foote RL, Sloan J, Petersen RC.

Donepezil and vitamin E for preventing cognitive dysfunction in small cell lung cancer patients: preliminary results and suggestions for future study designs. Support Care Cancer 2005; 13: 66-69.

187. Goetz MP, Toft D, Reid J, Ames M, Stensgard B, Safgren S, Adjei AA, Sloan J,

Atherton P, Vasile V, Salazaar S, Croghan G, Erlichman C. Phase I Trial of 17-Allylamino017-Demethoxygeldanamycin in Patients With Advanced Cancer. Journal of Clinical Oncology 2005; 23(6): 1078-1087.

186. Garces YI, Yang P, Parkinson J, Zhao X, Wampfler JA, Ebbert JO, Sloan JA. The

relationship between cigarette smoking and quality of life after lung cancer diagnosis. Chest 2004; 126(6): 1733-1741.

185. Dispenzieri A, Wiseman GA, Lacy MQ, Litzow MR, Anderson PM, Gastineau DA,

Tefferi A, Inwards DJ, Micallef INM, Ansell SM, Porrata L, Elliott MA, Lust JA, Greipp PR, Rajkumar SV, Fonseca R, Witzig TE, Erlichman C, Sloan JA, Gertz MA. A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Leukemia 2005; 19: 118-125.

184. Okuno SH, Foote RL, Olmscheid MA, Sloan JA, Sapiente RA, Novotny PJ, Anthes

ML, Loprinzi CL. Evaluation of an oral capsaicin lozenge for preventing radiation-induced mucositis. Journal of Cancer Integrative Medicine 2004; 2(4): 179-183.

183. Pockaj BA, Loprinzi CL, Sloan JA, Novotny PJ, Barton DL, Hagenmaier A, Zhang H,

43

Sloan CV, 5/7/2008

Lambert GH, Reeser KA, Wisbey JA. Pilot evaluation of black cohosh for the treatment of hot flashes in women. Cancer Invest. 2004; 22(4): 515-21.

182. Jatoi A, Suman VJ, Schaefer P, Block M, Loprinzi C, Roche P, Garneau S, Morton R,

Stella PJ, Alberts SR, Pittelkow M, Sloan J, Pagano R. A phase II study of topical ceramides for cutaneous breast cancer. Breast Cancer Research and Treatment 2003; 80(1): 99-104.

181. Pangman VC, Sloan J, Guse L. An Examination of Psychometric Properties of the

Mini-Mental State Examination and the Standardized Mini-Mental State Examination: Implications for Clinical Practice. Applied Nursing Research 2000; 13(4): 209-213.

180. Dy GK, Bekele L, Hanson LJ, Furth A, Mandrekar S, Sloan JA, Adjei AA.

Complementary and Alternative Medicine Use by Patients Enrolled Onto Phase I Clinical Trials. Journal of Clinical Oncology 2004; 22(23): 4758-4763.

179. Sloan JA, Scott-Findlay S, Nemecek A, Blood P, Trylinski C, Whittaker H, El Sayed S,

Clinch J, Khoo K. Mapping the journey of cancer patients through the health care system. Part 2: Methodological approaches and basic findings. Canadian Oncology Nursing Journal 2004; 14(4): 224-227.

178. Loprinzi CL, Barton DL, Carpenter LA, Sloan JA, Novotny PJ, Gettman MT,

Christensen BJ. Pilot Evaluation of Paroxetine for Treating Hot Flashes in Men. Mayo Clinic Proceedings; October 2004; 79(10): 1247-1251.

177. Jatoi A, Egner J, Loprinzi CL, Sloan JA, Novotny PJ, Dakhil SR, Mailliard JA, Klee

GG, Krook JE. Investigating the utility of serum cytokine measurements in a multi-institutional cancer anorexia/weight loss trial. Support Care Cancer 2004; 12: 640-644.

176. Sloan JA, Scott-Findlay S, Nemecek A, Blood P, Trylinski C, Whittaker H, El Sayed S,

Clinch J, Khoo K. Mapping the journey of cancer patients throughout the health care system. Part 1: Developing the research question. Canadian Oncology Nursing Journal 2004; 14(3): 183-186.

175. Norman GR, Sloan JA, Wyrwich KW. The truly remarkable universality of half a

standard deviation: confirmation through another look. Expert Review of Pharmacoeconomics and Outcomes Research 2004; 4(5): 581–585.

174. Svobodnik A, Yang P, Novotny PJ, Bass E, Garces YI, Jett JR, Bonner JA, Sloan JA.

Quality of Life in 650 Lung Cancer Survivors 6 Months to 4 Years after Diagnosis. Mayo Clinic Proceedings 2004; 79(8): 1024-1030.

173. Jatoi A, Rowland K, Loprinzi CL, Sloan JA, Dakhil SR, MacDonald N, Gagnon B,

Novotny PJ, Mailliard JA, Bushey TIL, Nair S, Christensen B. An Eicosapentaenoic Acid Supplement Versus Megestrol Acetate Versus Both for Patients With Cancer-Associated Wasting: A North Central Cancer Treatment Group and National Cancer Institute of Cancer Institute of Canada Collaborative Effort. Journal of Clinical Oncology 2004; 22(12): 2469–2476.

172. Lindor NM, Sloan J, Goldberg R, Bowen D, Nigon S, Roche A, Petersen G,

Thibodeau SN, Burgart L, Leontovich O, Morlan BW. Colorectal Tumor Microsatellite

44

Sloan CV, 5/7/2008

Instability Test Results: Perspectives from Patients. Hereditary Cancer in Clinical Practice 2004; 2(2): 69-75.

171. Shanafelt TD, Loprinzi C, Marks R, Novotny P, Sloan J. Are Chemotherapy Response

Rates Related to Treatment-Induced Survival Prolongations in Patients With Advanced Cancer? J Clin Oncol 2004; 22(10): 1966-1974.

170. Jatoi A, Ellison N, Burch PA, Quesenberry J, Shogren K, Sloan JA, Young CYF.

Prostate Cancer Patients with Maspin-Negative Tumors Can Live Over a Decade. Cancer Therapy 2004; 2: 173–176.

169. Jatoi A, Jett J, Sloan JA, Novotny P, Loprinzi C. A Pilot Study on Safety and

Pharmacokinetics of Infliximab for the Cancer Anorexia/Weight Loss Syndrome in Non-Small Cell Lung Cancer Patients. Supportive Care in Cancer 2004; 12: 859-863.

168. Sloan JA, Dueck A. Issues for Statisticians in Conducting Analyses and Translating

Results for Quality of Life End Points in Clinical Trials. Journal of Biopharmaceutical Statistics 2004; 14(1): 73-96.

167. Kaur JS, Roubidoux MA, Sloan JA, Novotny P. Can the Gail Model be Useful in

American Indian and Alaska Native Populations? Cancer 2004; 100(5): 906-912. 166. Krouse RS, Rosenfeld KE, Grant M, Aziz N, Byock I, Sloan J, Casarett D. Palliative

Care Research: Issues and Opportunities. Cancer Epidemiol Biomarkers Prev 2004; 13(3): 337-339.

165. Charboneau W, Goetz MP, Rubin J, Wong GY, Sloan JA, Novotny PJ, Lewis BD,

Welch TJ, Farrell MA, Maus TP, Lee RA, Reading CC, Petersen IA, Pickett DD. Painful Metastases Involving Bone: Feasibility of Percutaneous CT and US guided Radio frequency Ablation. Radiology 2004; 224(1): 87-97.

164. Perez DG, Loprinizi CL, Barton DL, Pockaj BA, Sloan JA, Novotny PJ, Christensen

BJ. Pilot Evaluation of Mirtazapine for the Treatment of Hot Flashes. J Support Oncol 2004; 2: 50 - 56.

163. Goetz MP, Callstrom MR, Charboneau JW, Farrell MA, Maus TP, Welch TJ, Wong

GY, Sloan JA, Novotny PJ, Petersen IA, Beres RA, Regge D, Capanna R, Saker MB, Gronemeyer DHW, Gevargez A, Ahrar K, Choti MA, deBaere TJ, Rubin J. Percutaneous Image-Guided Radiofrequency Ablation of Painful Metastases Involving Bone: A Multicenter Study. Journal of Clinical Oncology. 2004; 22(2): 300-306.

162. Adjei AA, Croghan GA, Erlichman C, Marks RS, Reid JM, Sloan JA, Pitot HC, Alberts

SR, Goldberg RM, Hanson LJ, Bruzek LM, Atherton P, Thibault A, Palmer PA, Kaufmann SH. A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin Cancer Res. 2003; 9(7): 2520-6.

161. Giuntoli RL II, Metzinger DS, DiMarco CS, Cha SS, Sloan JA, Keeney GL, Gostout

BS. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicatiors, surgical management, and adjuvant therapy. Obstetrical & Gynecological Survey 2003; 58(10): 663-665.

160. Croghan GA, Sloan JA, Croghan IT, Novotny P, Hurt RD, DeKrey WL, Mailliard JA,

45

Sloan CV, 5/7/2008

Ebbert LP, Swan DK, Walsh DJ, Wiesenfeld M, Levitt R, Stella P, Johnson PA, Tschetter L, Loprinzi C. Comparison of nicotine patch alone versus nicotine nasal spray alone versus a combination for treating smokers: a minimal intervention, randomized multicenter trial in a nonspecialized setting. Nicotine Tob Res. 2003; 5(2): 181-7.

159. Jatoi A, Kumar S, Sloan JA, Nguyen PL. On appetite and its loss. J Clin Oncol.

2003; 21(9 Suppl): 79-81. 158. Sloan JA. Quality-of-life meta-analysis: why treat it differently? J Clin Oncol. 2003;

21(7):1422. 157. Goetz MP, Erlichman C, Windebank AJ, Reid JM, Sloan JA, Atherton P, Adjei AA,

Rubin J, Pitot H, Galanis E, Ames MM, Goldberg RM. Phase I pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors. J Clin Oncology 2003; 21(20): 3761-9.

156. Marks RS, Graham DL, Sloan JA, Hillman S, Fishkoff S, Krook JE, Okuno SH,

Mailliard JA, Fitch TR, Addo F. A Phase II Study of the Dolastatin 15 Analogue LU 103793 in the Treatment of Advanced Non-Small Cell Lung Cancer. Am J Clin Oncol. 2003; 26(4): 336-7.

155. Sloan, JA. Assessing the clinical significance of quality of life (QOL) measures.

Society of Clinical Research Associates November 2003; 38: 23–25. 154. Jacobson SD, Loprinzi CL, Sloan JA, Wilke JL, Novotny PJ, Okuno SH, Jatoi A,

Moynihan TJ. Glutamine does not prevent paclitaxel – associated myalgias and arthraglias. The Journal of Supportive Oncology 2003; 1(4): 274–278.

153. Gill P, Kaur JS, Rummans T, Novotny PJ, Sloan JA. The hospice patient’s primary

caregiver: What is their quality of life? Journal of Psychosomatic Research 2003; 55: 445-451.

152. Schaefer PL, Marks RS, Mahoney MR, Sloan JA, Bauman MD, Tazelaar HD, Kugler

JW, Mailliard JA, Ebbert LP, Wiesenfeld M. Randomized phase II study of daily versus continuous-infusion schedules of Topotecan in the treatment of extensive-stage small cell lung cancers. Am J Clin Oncol 2003; 26(3): 236-240.

151. Sloan JA, Vargas-Chanes D, Kamath CC, Sargent DJ, Novotny PJ, Atherton P,

Allmer C, Fridley BL, Frost MH, Loprinzi CL. Detecting worms, ducks and elephants: A simple approach for defining clinically relevant effects in quality-of-life measures. J Cancer Integrative Medicine 2003; 1(1): 41-47.

150. Jacobson SD, Loprinzi CL, Sloan JA, Wilke JL, Novotny PJ, Okuno SH, Jatoi A,

Moynihan TJ. Glutamine Does Not Prevent Paclitaxel-Associated Myalgias and Arthralgias. Journal of Supportive Oncology 2003; 1(4): 274-8.

149. Jatoi A, Hillman S, Stella PJ, Mailliard JA, Sloan J, Vanone S, Cannon MW, Kutteh, L,

Kanard A, Jett JR. Daily activities: exploring their spectrum and prognostic impact in older chemotherapy-treated lung cancer patients. Support Care Cancer 2003; 11: 460-464.

148. Roubidoux MA, Kaur JS, Griffith KA, Sloan J, Wilson C, Novotny P, Lobell M.

46

Sloan CV, 5/7/2008

Correlates of mamogram density in Southwestern Native-American Women. Cancer Epidemiology Biomarkers & Prevention 2003; 12: 552-558.

147. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related

quality of life. The remarkable universality of a half a standard deviation. Medical Care 2003; 41(5): 582-592. (Nominated for outstanding QOL article of the year – ISOQOL 2004)

146. Goldberg RM, Kaufmann SH, Atherton P, Sloan JA, Adjei AA, Pitot HC, Alberts SR,

Rubin J, Miller LL, Erlichman C. A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin. Annals of Oncology 2002; 13: 1674-1680.

145. Gostout BS, Poland GA, Calhoun ES, Sohni YR, Giuntoli RL, McGovern RM, Sloan

JA, Cha SS, Persing DH. TAP1, TAP2 and HLA-DR2 alleles are predictors of cervical cancer risk. Gynecologic Oncology 2003; 88: 326-332.

144. Shanafelt TD, Sloan JA, Habermann TM. The well-being of physicians. The

American Journal of Medicine 2003; 114(6): 513-519. 143. Jatoi A, Ellison N, Burch PA, Sloan JA, Dakhil SR, Novotny P, Tan W, Fitch TR,

Rowland KM, Young CYF, Flynn PJ. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 2003; 97(6): 1442-1446.

142. Sloan J, Symonds T, Vargas-Chanes D, Fridley B. Practical guidelines for assessing

the clinical significance of health-related quality of life changes within clinical trials. Drug Information Journal 2003; 37: 23-31.

141. Atherton PJ, Jasperson B, Nibbe A, Clement-Brown KA, Allmer C, Novotny P,

Erlichman C, Sloan JA. What happened to all the patients? Event charts for summarizing individual patient data and displaying clinically significant changes in quality of life data. Drug Information Journal 2003; 37:11-21.

140. Swensen SJ, Jett JR, Hartman TE, Midthun DE, Sloan JA, Sykes AM, Aughenbaugh

GK, Clemens ME. Lung cancer screening with CT: Mayo Clinic experience. Radiology 2003; 226(3): 756-761.

139. Hurt RD, Krook JE, Croghan IT, Loprinzi CL, Sloan JA, Novotny PJ, Kardinal CG,

Knost JA, Tirona MT, Addo F, Morton RF, Michalak JC, Schoefer PL, Porter PA, Stella PJ. Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking. Journal of Clinical Oncology 2003; 21(5): 914-920.

138. Roubidoux MA, Salmon Kaur J, Griffiths KS, Sloan J, Wilson C, Novotny P,Lobell M.

Mammogram Density and Diabetes in Southwestern American Indian Women. 137. Barton D, Loprinzi C, Quella S, Sloan J, Pruthi S, Novotny P.

Depomedroxyprogesterone Acetate for Hot Flashes. Journal of Pain and Symptom Management 2002; 24(6): 603-607.

136. Kozelsky TF, Meyers GE, Sloan JA, Shanahan TG, Dick SJ, Moore RL, Engeler GP,

Frank AR, McKone TK, Urias RE, Pilepich MV, Novotny PJ. Phase 3 Double-Blind Study of Glutamine Versus Placebo for the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy. Journal of Clinical Oncology 2003; 21(9): 1669-

47

Sloan CV, 5/7/2008

1674. 135. Barton D, Loprinzi C, Quella S, Sloan J, Pruthi S, Novotny P.

Depomedroxyprogesterone Acetate for Hot Flashes. Journal of Pain and Symptom Management 2002; 24(6): 603-607.

134. Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, Krood JE, Wilwerding MB, Rowland

KM Jr, Camoriano JK, Novotny PJ, Christensen BJ. Randomized Comparison of Megestrol Acetate Versus Dexamethasone Verses Fluoxymesterone for the Treatment of Cancer Anorexia/Cachexia. Journal of Clinical Oncology 1999; 17(10): 3299-3306.

133. Jatoi A, Hillman S, Stella PJ, Mailliard JA, Sloan JA, Vanone S, Cannon M, Kutteh L,

Kenard A, Jett J. Daily Activities: Exploring their spectrum and prognostic impact in older, chemotherapy-treated lung cancer patients. Supportive Care in Cancer 2003; 11:460-464.

132. Adjei AA, Dy GK, Erlichman C, Reid JM, Sloan JA, Pitot HC, Alberts SR, Goldberg

RM, Hanson LJ, Atherton PJ, Watanabe Y, Geary RS, Holmlund J, Dorr FA. A Phase I Trial of ISIS 2503, an Antisense Inhibitor of H-ras, in Combination with Gemcitabine in Patients with Advanced Cancer. Clinical Cancer Research 2003; 9: 115-123.

131. Hobday TJ, Kugler JW, Mahoney MR, Sargent DJ, Sloan JA, Fitch TR, Krook ME,

O'Connell MJ, Mailliard JA, Tirona MT, Tschetter LK, Cobau CD, Goldberg RM. Efficacy and Quality-of-Life Data are Related in a Phase II Trial of Oral Chemotherapy in Previously Untreated Patients with Metastatic Colorectal Carcinoma. Journal of Clinical Oncology 2002; 20(23): 4574-4580.

130. Frost MH, Sloan JA. Quality of Life Measurements: A soft outcome-or is it? The

American Journal of Managed Care 2002; 8(18): S574-S579. 129. Ansell SM, Witzig TE, Kurtin PJ, Sloan JA, Jelinek DF, Howell KG, Markovic SN,

Habermann TM, Klee GG, Atherton PJ, Erlichman C. Phase I study of interleukin-12 in combination with rituximab in patients with b-cell non-hodgkins lymphoma. Blood 2002; 99(1): 67-74.

128. Pitot HC, Reid JM, Sloan JA, Ames MM, Adjei AA, Rubin J, Bagniewski PG, Atherton

P, Rayson D, Goldberg RM, Erlichman C. A phase I study of bizelesin (NSC15291) in patients with advanced solid tumors. Clinical Cancer Research 2002; 8(3): 712-717.

127. Jatoi A, Ellison N, Burch PA, Sloan JA, Dakhil SR, Novotny P, Tan W, Fitch TR,

Rowland KM, Young CYF, Flynn PJ. (In Press). A Phase II Trial of Green Tea in the Treatment of Androgen-Independent Metastatic Prostate Cancer. Cancer 2003; 97: 1442-6.

126. Croghan GA, Sloan JA, Croghan IT, Novotny P, Hurt RD, DeKrey WL, Mailliard JA,

Ebbert LP, Krook JE, Walsh DJ, Wiesenfeld M, Levitt R, Hatfield AK, Tschetter LK, Loprinzi C. (In Press) Comparison of a 15 mg/16 Hour Nicotine Patch Alone Versus Nicotine Nasal Spray Alone Versus Both for Treating Smokers: A Randomized Multicenter Trial. Journal of Tobacco and Nicotine Research; 2002.

125. Hammack JE, Michalak JC, Loprinzi CL, Sloan JA, Novotny PJ, Soori GS, Tirona MT,

Rowland Jr. KM, Stella PJ, Johnson JA. Phase III evaluation of nortriptyline for

48

Sloan CV, 5/7/2008

alleviation of symptoms of cisplatinum-induced peripheral neuropathy. Pain 2002; 98: 195-203.

124. Loprinzi CL, Barton DL, Sloan, JA, Zahasky KM., Smith DAR, Pruthi, S, Novotny PJ,

Perez EA. Pilot Evaluation of Gabapentin for Treating Hot Flashes. Mayo Clinic Proceedings 2002; 77: 1159-1163.

123. Adjei AA, Reid JM, Erlichman C, Sloan JA, Pitot HC, Alberts SR, Goldberg RM,

Hanson LJ, Ruben S, Boerner SA, Atherton P, Ames MM, Kaufmann SH. A Phase I and Pharmacologic Study of Pyrazoloacridine (NSC 366140) and Carboplatin in Patients with Advanced Cancer. Investigational New Drugs 2002; 20: 297-304.

122. Cuddihy MT, Gabriel SE, Sloan JA, Crowson CS, Melton LJ. Osteoporosis Health

Beliefs Among Postmenopausal Women With a History of Distal Forearm Fracture. Clinical Journal of Women's Health 2002; 2(2): 79-87.

121. Schroeder G, Sloan, JA, Cha S, Atherton P, Allmer C, Erlichman C. Phase I

Oncology Clinical Trials for Related Subpopulations: The Power Walk Design. Drug Information Journal 2002; 36: 581-593.

120. Marks RS, Graham D, Sloan JA, Hillman S, Fishkoff S, Krook JE, Okuno SH, Mailliard

JA, Fitch TR, Addo F. A Phase II Study of the Dolastatin 15 Analogue LU 103793 in the Treatment of Advanced Non Small Lung Cancer. American Journal of Clinical Oncology 2003; 26(4): 336-7.

119. Erlichman C, Sloan J. A phase I study of sequential irinotecan and 5-

fluorouracil/leucovorin. (In Press, 2002). Annals of Oncology. 118. Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ, Mailliard JA, Halyard MY,

Pruthi S, Novotny PJ, Rummans TA. Phase III evaluation of Fluoxetine for treatment of hot flashes. Journal of Clinical Oncology 2002; 20(6): 1578-1583.

117. Varricchio CG, Sloan JA. The need for and characteristics of randomized, Phase III

trials to evaluate symptom management in patients with Cancer. Editorial, Journal of the National Cancer Institute 2002; 94(16): 1184-1185.

116. Callstrom MR, Charboneau JW, Goetz MP, Rubin J, Wong GY, Sloan JA, Novotny

PJ, Lewis BD, Welch TJ, Farrell MA, Maus TP, Lee RA, Reading CC, Petersen IA, Pickett DD. Painful metastases involving bone: feasibility of percutaneous CT- and US-guided radio-frequency ablation. Radiology 2002; 224: 87-97.

115. Symonds T, Berzon R, Marquis P, Rummans T, Sloan, JA, and the Clinical

Significance Consensus Meeting Group. Clinical Significance of Quality of Life results: practical considerations for specific audiences. Mayo Clinic Proceedings 2002; 77: 572-583.

114. Sprangers MAG, Moinpour CM, Moyniyhan, TJ, Patrick DL, Revicki DA, Sloan, JA,

and the Clinical Significance Consensus Meeting Group. Assessing Meaningful Changes in Quality of Life Over Time: A User’s Guide for Clinicians. Mayo Clinic Proceedings 2002; 77: 561-571.

113. Benrud-Larson LM, Dewar MS, Sandroni P, Rummans T, Haythornwaite JA, Low P.

Quality of life in patients with postural tachycardia syndrome. Mayo Clinic

49

Sloan CV, 5/7/2008

Proceedings 2002; 77: 531-537. 112. Cella D, Bullinger M, Scott C, Barofsky I, Sloan JA, and the Clinical Significance

Consensus Meeting Group. Group vs Individual Approaches to Understanding the Clinical Significance of Differences or Changes in Quality of Life. Mayo Clinic Proceedings 2002; 77: 384-392.

111. Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR, Sloan JA, and the Clinical

Significance Consensus Meeting Group. Methods to Explain the Clinical Significance of Health Status Measures. Mayo Clinic Proceedings 2002; 77: 371-383.

110. Frost MH, Bonomi AE, Estwing-Ferrans C, Wong GY, Hays RD, Sloan JA, and the

Clinical Significance consensus Meeting Group. Patient, Clinician and Population Perspectives on Determining the Quality of Life Scores. Mayo Clinic Proceedings 2002; 77: 488-494.

109. Sloan JA, Aaronson N, Cappelleri JC, Fairclough DL, Varricchio C, and the Clinical

Significance Consensus Meeting Group. Assessing the Clinical Significance of Single Items Relative to Summated Scores. Mayo Clinic Proceedings 2002; 77: 479-487.

108. Sloan JA, Goldberg RM, Sargent DJ, Vargas-Chanes D, Nair S, Cha SS, Novotny PJ,

Poon MA, O'Connell MJ, Loprinzi CL. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. Journal of Clinical Oncology 2002; 20(6): 1491-1498.

107. Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ, Mailliard JA, Halyard MY,

Pruthi S, Novotny PJ, Rummans TA. Phase III Evaluation of Fluoxetine for Treatment of Hot Flashes. Journal of Clinical Oncology 2002; 20(6): 1578-1583.

106. Adjei AA, Reid JM, Diasio RB, Sloan JA, Smith DA, Rubin J, Pitot HC, Alberts ST,

Goldberg RM, Hanson LJ, Atherton P, Ames MM, Erlichman C. Comparative Pharmacokinetic Study of Continuous Venous Infusion Fluorouracil and Oral Fluorouracil with Eniluracil in Patients with Advanced Solid Tumors. Journal of Clinical Oncology 2002; 20(6): 1683-1691.

105. Sloan JA, Cella D, Frost M, Guyatt GH, Sprangers M, Symonds T, and the Clinical

Significance Consensus Meeting Group. Assessing Clinical Significance in Measuring Oncology Patient Quality of Life: Introduction to the Symposium, Content Overview, and Definition of Terms. Mayo Clinic Proceedings 2002; 77: 367-370.

104. Sloan JA, Sargent DJ, Lindman J, Allmer C, Vargas-Chanes D, Creagan ET, Bonner

JA, O'Connell MJ, Dalton RJ, Rowland KM, Brooks BJ, Laurie JA. A new graphic for quality adjusted life years (Q-TWIST) survival analysis: The Q-TWIST plot. Quality of Life Research 2002; 11: 37-45.

103. Swensen SJ, Jett JR, Sloan JA, Midthun DE, Hartman TE, Sykes AM, Aughenbaugh

GL, Zink FE, Hillman SL, Noetzel GR, Marks RS, Clayton AC, Pairolero PC. Screening for Lung Cancer with Low-Dose Spiral Computed Tomography. American Journal Respiratory Critical Care Med. 2002; 165: 508-513.

102. Jatoi A, Yamashita J, Sloan JA, Novotny PJ, Windschitl HE, Loprinzi CL. Does

Megestrol acetate down-regulate interleukin-6 in patients with cancer-associated anorexia and weight loss? A North Central Cancer Treatment Group investigation.

50

Sloan CV, 5/7/2008

Support Care Cancer 2002; 10: 71-75. 101. Colon-Otero G, Niedringhaus RD, Hillman SH, Geyer S, Sloan JA, Krook JE,

Windschitl HE, Marks RS, Wiesenfeld M, Tschetter LK, Jett J. A Phase II Trial of Edatrexate, Vinblastine, Adriamycin, Cisplastin, and Filgrastim (EVAC/G-CSF) in Patients with Non-small Cell Carcinoma of the Lungs. American Journal of Clinical Oncology 2001; 24(6): 551-555.

100. Barton D, LaVasseur B, Loprinzi C, Novotny P, Wilwerding MB, Sloan JA.

Venlafaxine for the Control of Hot Flashes: Results of a Longitudinal Continuation Study. Oncology Nursing Forum 2002; 29(1): 33-40.

99. Jatoi A, Windshitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, Pundaleeka S,

Kardinal CG, Fitch TR, Krook JE, Novotny PJ, Christensen B. Dronabinol Versus Megestrol Acetate Versus Combination Therapy for Cancer-Associated Anorexia: A North Central Cancer Treatment Group Study. Journal of Clinical Oncology 2002; 20(2): 567-573.

98. Sloan JA. Asking the obvious Questions Regarding Patient Burden. Journal of

Clinical Oncology 2002; 20(1): 4-6. 97. Sloan JA, Loprinzi CL, Novotny PJ, Barton DL, Lavasseur BI, Windschitl, H.

Methodologic lessons learned from hot flash studies. Journal of Clinical Oncology 2001; 19(23): 4280-4290.

96. Sanderson CL, Sloan JA, Patten CA, Bonner JA, Geyer SM, McGinnis WL, Stella PJ,

Marks RS. Smoking behavior change of 226 patients with newly diagnosed stage IIIA/IIIB non-small cell lung cancer. Journal of Pain and Symptom Management 2002; 11: 1-7.

95. Sloan JA, Loprinzi CL, Laurine JA Novotny PJ, Vargas-Chanes D, Krook JE,

O’Connell MJ, Kugler JW, Tirona MT, Kardinal CG, Wiesenfeld M, Tschetter LK, Hatfield AK, Schafer PL. A simple stratification factor prognostic for survival in advanced cancer: The Good/Bad/Uncertain index. Journal of Clinical Oncology 2001; 19: 3539-3546.

94. O’Rourke DJ, Klaasen KS, Sloan JA. Redesigning nighttime care for personal care

residents. Journal of Gerontological Nursing 2001; 27: 30-37. 93. Sloan JA, Atherton P, Reid J, Pitot HC, Erlichman C, Schaaf L. Limited sampling

models for CPT-11, SN-38, and SN-38 glucuronide. Cancer Chemother Pharmacol 2001; 48: 241-249.

92. Galanis E, Goldberg R, Reid J, Atherton P, Sloan JA, Pitot H, Rubin J, Adjei AA,

Burch P, Safgren SL, Witzig TE, Ames MM, Erlichman C. Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2’-deoxyuridine (IdUrd). Annals of Oncology 2001; 12: 701-707.

91. Jatoi A, Loprinzi CL, Sloan JA, Klee GG, Windschitl HE, O’Connell M. Neuropeptide

Y, Leptin, and Cholecystokinin 8 in patients with advanced cancer and anorexia: A North Central Cancer Treatment Group Investigation. Cancer 2001; 92: 629-633.

90. Erlichman C, Adjei AA, Alberts SR, Sloan JA, Goldberg RM, Pitot HC, Rubin J,

51

Sloan CV, 5/7/2008

Atherton PJ, Klee GG, Humphrey R. Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566. Annals of Oncology 2001; 12: 389-395.

89. Sloan JA, Tolman DE, Anderson JD, Sugar AW, Wolfaardt JF, Novotny P. Patients

with reconstruction of craniofacial or intraoral defects: Development of instruments to measure quality of life. The International Journal of Oral and Maxillofacial Implants 2001; 16: 225-245.

88. Sloan JA, Varricchio C. Quality of life endpoints in prostate chemoprevention trials.

Urology 2001; 57: 235-240. 87. Lee JJ, Lieberman R, Sloan JA, Piantadosi S, Lippman S. Design considerations for

efficient prostate cancer chemoprevention trials. Urology 2001; 57: 205-212. 86. Dudgeon DJ, Kristjanson L, Sloan JA, Lertzman M, Clement K. Dyspnea in cancer

patients: Prevalence and associated factors. J Pain Symptom Manage 2001; 21(2): 95-102.

85. Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL, Novotny

PJ, Dakhil SR, Rodger K, Rummans TA. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized controlled trial. Lancet 2000; 356: 2059-2063.

84. Rummans TA, Bostwick JM, Clark MM (For the Mayo Clinic Cancer Center Quality of

Life Working Group). Maintaining quality of life at the end of life. Mayo Clinic Proceedings 2000; 75: 1305-1310.

83. Alberts SR, Erlichman C, Sloan JA, Okuno SH, Burch PA, Rubin J, Pitot HC,

Goldberg RM, Adjei A, Atherton PJ, Kaufmann SH. Phase I trial of gemcitabine and CPT-11 given weekly for 4 weeks every 6 weeks. Annals of Oncology 2001; 12: 627-631.

82. Colon-Otero G, Niedringhaus RD, Hillman S, Geyer S, Sloan JA, Krook JE, Windschitl

H, Marks R, Wiesenfeld M, Tschetter L, Jett JJ. A phase II trial of Edatrexate, Vinblastine, Adriamycin, Cisplatin and Filgrastim (EVAC/G-CSF) in patients with advanced non-small cell carcinoma of the lungs: A North Central Cancer Treatment Group Trial. American Journal of Clinical Oncology 2001; 24(6): 551-555.

81. Sloan JA, Bonner JA, Hillman SL, Allmer C, Shanahan TG, Brooks BJ, Marks S,

Vargas D, Jett JR. A quality-adjusted re-analysis of a phase III trial comparing once-daily thoracic radiation versus twice-daily thoracic radiation in patients with limited stage small cell lung cancer. Int.J Radiat Oncol Biol 2002; 52(2): 371-381.

80. Jatoi A, Kumar S, Sloan JA, Nguyen PL. The Art of Oncology: When the Tumor is not

the Target on Appetite and Its Loss. Journal of Clinical Oncology 2000; 18(15): 2930-2932.

79. Pitot HC, Goldberg RM, Reid JM, Sloan JA, Atherton Skaff P, Erlichman C, Rubin J,

Burch PA, Adjei AA, Alberts SA, Schaaf LJ, Elfring G, Miller LL. Phase I dose-finding and pharmacokinetic trial of Irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. Clinical Cancer Research 2000; 6: 2236-2244.

52

Sloan CV, 5/7/2008

78. Frost MH, Schaid DJ, Sellers TA, Slezak JM, Arnold PG, Woods JE, Petty PM, Johnson JL, Sitta DL, McDonnell SK, Rummans TA, Jenkins RB, Sloan JA, Hartmann LC. Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA 2000; 284: 319-324.

77. Sloan JA, Novotny PJ, Loprinzi CL. Design and analysis of cancer control studies

using the SAS system. SUGI 25 Proceedings, Indianapolis, Indiana, paper 2000; 259-25.

76. Adjei AA, Erlichman C, Sloan JA, Reid JM, Pitot HC, Goldberg RM, Peethambaram

P, Atherton P, Hanson LJ, Alberts SR, Jett J. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol 2000; 18: 1748-1757.

75. Loprinzi CL, Zahasky KM, Sloan JA, Novotny PJ, Quella SK. Tamoxifen-induced hot

flashes. Clinical Breast Cancer 2000; 1: 20-24. 74. Quella SK, Loprinzi CL, Barton DL, Knost JA, Sloan JA, LaVasseur BI, Swan D,

Krupp KR, Miller KD, Novotny PJ. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial. J Clin Oncol 2000; 18: 1068-1074.

73. Martenson JA, Bollinger JW, Sloan JA, Novotny PJ, Urias RE, Michalak JC,

Shanahan TG, Mailliard JA, Levitt R. Sucralfate in the prevention of treatment-induced diarrhea in patients receiving pelvic radiation therapy: A North Central Cancer Treatment Group Phase III Double-Blind Placebo-Controlled Trial. J Clin Oncol 2000; 18: 1239-1245.

72. Adjei AA, Klein CE, Kastrissios H, Goldberg RM, Alberts SR, Pitot HC, Sloan JA, Reid

JM, Hanson LJ, Atherton P, Rubin J, Erlichman C. Phase I and Pharmacokinetic Study of Irinotecan and Docetaxel in Patients With Advanced Solid Tumors: Preliminary Evidence of Clinical Activity. J Clin Oncol 2000; 18: 1116-1123.

71. Bonner JA, Sloan JA, Rowland, Jr., KM, Klee GG, Kugler JW, Mailliard JA,

Wiesenfeld M, Krook JE, Maksymiuk AW, Shaw EG, Marks RS, Perez EA. Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer. Clinical Cancer Research 2000; 6: 597-601.

70. Jatoi A, Loprinzi CL, Sloan JA, Goldberg RM. Is ATP (Adenosine 5’-Triphosphate),

like STP, a performance-enhancing additive for the tanks of cancer patients? Journal of the National Cancer Institute 2000; 92: 290-291.

69. Adjei AA, Erlichman C, Davis JN, Cutler DL, Sloan JA, Marks RS, Hanson LJ,

Svingen PA, Atherton P, Bishop WR, Kirschmeier P, Kaufmann SH. A phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity. Cancer Research 2000; 60: 1871-1877.

68. Lobchuk MM, Kristjanson L, Degner L, Blood P, Sloan JA. Wahrnehmung der

Symptombelastung bei Lungenkrebspatienten: I. Ubereinstimmung zwischen Patienten und den sie hauptsachlich pflegenden Angehorigen. Pflege 1999; 12: 352-361.

67. Weitz JJ, Marschke, Jr., RF, Sloan JA, Grill JP, Jett JR, Knost JA, Hatfield AK, Zenk

53

Sloan CV, 5/7/2008

DW, Bate WW, Schaefer PL. A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer. Lung Cancer 2000; 28(2): 157-162.

66. Anderson PM, Markovic SN, Sloan JA, Clawson ML, Wylam M, Arndt CAS, Smithson

WA, Burch P, Gornet M, Rahman E. Aerosol granulocyte macrophage-colony stimulating factor: A low toxicity, lung-specific biological therapy in patients with lung metastases. Clinical Cancer Research 1999; 5: 2316-2323.

65. Loprinzi CL, Johnston PB, Sloan JA, Novotny P, Ellison N. Have medical oncologists

recently modified surveillance testing patterns for melanoma and/or breast cancer survivors? Cancer Research Therapy and Control 1999; 9: 205-214.

64. Sloan JA, Loprinzi CL, Novotny PJ, Okuno S, Nair S, Barton DL. Sex differences in

Fluorouracil-induced stomatitis. Journal of Clinical Oncology 2000; 18: 412-420. 63. Wagner JL, Alberts SR, Sloan JA, Cha S, Killian J, O’Connell MJ, Van Grevenhof P,

Lindman J, Chute CG. Incremental costs of enrolling cancer patients in clinical trials: A population-based study. J Natl Cancer Inst 1999; 91: 847-853.

62. Fonseca R, O’Neill BP, Foote RL, Grill JP, Sloan JA, Frytak S. Cerebral toxicity in

patients treated for small cell carcinoma of the lung. Mayo Clin Proc 1999; 74: 461-465.

61. Bonner JA, Sloan JA, Shanahan TG, Brooks BJ, Marks RS, Krook JE, Gerstner JB,

Maksymiuk A, Levitt R, Mailliard JA, Tazelaar HD, Hillman S, Jett JR. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol 1999; 17: 2681-2691.

60. Bretscher M, Rummans T, Sloan JA, Kaur J, Bartlett A, Borkenhagen L, Loprinzi C.

Quality of life in hospice patients - A Pilot Study. Psychosomatics 1999; 40: 309-313. 59. Okuno SH, Woodhouse CO, Loprinzi CL, Sloan JA, LaVasseur BI, Clemens-Schutjer

D, Swan D, Axvig C, Ebbert LP, Tria Tirona MRB, Michalak JC, Pierson N. Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fuorouracil (5-FU)-based chemotherapy. American Journal of Clinical Oncology 1999; 22(3): 258-261.

58. Sloan JA, Cha SS, Wagner JL, Albert SR, Lindman J, Allmer C. Analyzing oncology

patient health care costs using the SAS system. Proceedings of SUGI 1999; 24: 1540-1545.

57. Mandrekar J, Sargent DJ, Novotny PJ, Sloan JA. A general Gibbs sampling

algorithm for analyzing linear models using the SAS system. Proceedings of SUGI 24 1999; 1644-1649.

56. Pitot HC, McElroy EA, Jr., Reid JM, Windebank AJ, Sloan JA, Erlichman C,

Bagniewski PG, Walker DL, Rubin J, Goldberg RM, Adjei AA, Ames MM. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Clinical Cancer Research 1999; 5: 525-531.

55. Galanis E, Frytak S, Rowland K, Sloan JA, Lennon VA. Neuronal autoantibody titers

54

Sloan CV, 5/7/2008

in the course of small cell lung carcinoma and platinum associated neuropathy. Cancer Immunol Immunother 1999; 48: 85-90.

54. Sloan JA, Nemecek AM, Blood P, Scott-Findlay S, Trylinski C, Whittaker H, El Sayed

S, Clinch J, Khoo J. The trajectory of cancer patients through the Manitoba health care system. I. Framing the research question. Cancer Prevention and Control, 1998.

53. Sloan JA, Nemecek AM, Blood P, Scott-Findlay S, Trylinski C, Whittaker H, El Sayed

S, Clinch J, Khoo J. The trajectory of cancer patients through the Manitoba health care system. II. Methodology and basic findings. Cancer Prevention and Control, 1998.

52. Sloan JA, Scott-Findlay S, Nemecek AM, Blood P, Trylinski C, Whittaker H, El Sayed

S, Clinch J, Khoo K. The trajectory of cancer patients through the Manitoba health care system. III. Developing a staging methodology. Cancer Prevention and Control, 1998.

51. Loprinzi CL, Kugler JW, Sloan JA, Rooke TW, Quella SK, Novotny P, Mowat RB,

Michalak JC, Stella PJ, Levitt R, Tschetter LK, Windschilt H. Lack of effect of coumarin in women with lymphedema after treatment for breast cancer. New England Journal of Medicine 1999; 340: 346-350.

50. Goodridge DM, Sloan JA, LeDoyen YM, McKenzie J, Knight WE, Gayari M. Risk

assessment scores, prevention strategies and the incidence of pressure ulcers among the elderly in four Canadian health care facilities. Canadian Journal of Nursing Research 1998; 30(2): 23-44.

49. Sargent DJ, Sloan JA, Cha S. Sample size and design considerations for phase II

clinical trials with correlated observations. Controlled Clinical Trials 1999; 20: 242-252.

48. Marschke RF, Grill JP, Sloan JA, Wender DB, Levitt R, Mailliard JA, Gerstner JB,

Ghosh C, Morton RF, Jett JR. Phase II Study of High-Dose Somatostatin Analogue in Patients either Previously Treated or Untreated who have Extensive-Stage Small Cell Lung Cancer. American Journal of Clinical Oncolog 1999; 22(1): 15-17.

47. Sloan JA, O’Fallon JR, Suman VJ, Sargent DJ. Incorporating quality of life

measurement in oncology clinical trials. Proceedings of the American Statistical association 1998; 282-287.

46. Loprinzi CL, Pisansky TM, Fonseca R, Sloan JA, Zahasky KM, Quella SK, Novotny

PJ, Rummans TA, Dumesic DA, Perez EA. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 1998; 16: 2377-2381.

45. Alberts SR, Erlichman C, Reid JM, Sloan JA, Ames MM, Richardson RL, Goldberg

RM. Phase I study of the duocarmycin semi-synthetic derivative KW-2189 given daily for 5 days every 6 weeks. Clinical Cancer Research 1998; 4:2111-2117.

44. Degner LF, Davison J, Sloan JA, Mueller B. Development of a scale to measure

information needs in cancer care. Journal of Nursing Measurement 1998; 6(2): 137-153.

55

Sloan CV, 5/7/2008

43. Atherton Skaff P, Sloan JA. Design and analysis of equivalence clinical trials via the

SAS system. Proceedings of SUGI 23 1998; 1166-1171. (best paper award) 42. Sloan JA, Novotny PJ, Loprinzi CL. Analyzing quality of life (QOL) endpoints in

clinical trials via the SAS system. Proceedings of SUGI 23 1998; 1213-1222. 41. Barton DL, Loprinzi CL, Quella SK, Sloan JA, Veeder MH, Egner JR, Fidler P, Stella

PJ, Swan DK, Vaught NL, Novotny P. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. Journal of Clinical Oncology 1998; 16: 495-500.

40. Quella SK, Loprinzi CL, Sloan JA, Vaught NL, DeKrey WL, Fischer T, Finck G,

Pierson N, Pisansky TM. Long-term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer 1998; 82: 1784-1788.

39. Finck G, Barton D, Loprinzi CL, Quella S, Sloan JA. Definitions of hot flashes in

breast cancer survivors. Journal of Pain and Symptom Management 1998; 16(5): 327-333.

38. Bonner JA, McGinnis WL, Stella PJ, Marschke RF, Sloan JA, Shaw EG, Maillard JA,

Creagan, E.T., Ahuja, R.K, Johnson, P.A. The Possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced non-small cell lung carcinoma: results of a north central cancer treatment group phase III study. Cancer 1998; 82: 1037-1048.

37. Degner L, Sloan JA, Venkatesh P. The control preferences scale. Canadian Journal

of Nursing Research 1997; 29(3): 21-43. 36. Goldberg RM, Reid JM, Ames MM, Sloan JA, Rubin J, Erlichman C, Kuffel MJ, Fitch

TR. A phase I and pharmacologic trial of fazarabine (Ara-AC) with G-CSF. Clinical Cancer Research 1997; 3: 2363-2370.

35. Sloan JA, Loprinzi CL, Kuross SA, Miser AW, O’Fallon JR, Mahoney MR, Heid IM,

Bretscher ME, Vaught, NL. Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. Journal of Clinical Oncology 1998; 16: 3662-3673.

34. Chalmers KI, Bramadat IJ, Sloan JA. Development and testing of the primary health

care questionnaire (PHCQ): Results with students and faculty in diploma and degree nursing programs. Canadian Journal of Nursing Research 1997; 29(1): 79-96.

33. Colon-Otero G, Marschke R, Camoriano JK, Sorensen JM, Sloan JA, Richardson RL.

A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas. The Cancer Journal from Scientific American 1997; 3: 297-302.

32. Degner LF, Kristjanson LJ, Bowman D, Sloan JA, Carriere KC, O’Neil J, Bilodeau B,

Watson P, Mueller B. Information needs and decisional preferences in women with breast cancer. JAMA 1997; 277(18): 1485–1492.

31. Ellison N, Loprinzi CL, Kugler J, Hatfield A, Miser A, Sloan JA, Wender D, Rowland K,

Molina R, Cascino T, Vukov A, Dhaliwal H, Ghosh C. Phase III placebo-controlled trial

56

Sloan CV, 5/7/2008

of capsaicin cream in the management of surgical neuropathic pain in cancer patients. Journal of Clinical Oncology 1997; 15(8): 2974–80.

30. Lobchuk MM, Kristjanson L, Degner L, Blood P, Sloan JA. Perceptions of symptom

distress in lung cancer patients: I.Congruence between patients and primary family caregivers. Journal of Pain & Symptom Management 1997; 14(3): 136–146.

29. Loprinzi CL, Abu-Ghazale S, Sloan JA, vanHaelst-Pisani C, Hammer AM, Rowland

KM, Law M, Windschitl HE, Kaur JS, Ellison N. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. Journal of Clinical Oncology 1997; 15: 969-973.

28. McGinnis W, Loprinzi CL, Buskirk S, Sloan JA, Drummond R, Frank A, Shanahan T,

Kahanic S, Moore R, Schild S, Humphrey S. Placebo-controlled trial of sucralfate for inhibiting radiation-induced esophagitis. Journal of Clinical Oncology 1997; 15: 1239-1243.

27. Loprinzi CL, Sloan JA, Kugler J. Coumarin-Induced Hepatotoxicity. Letter-to-the-

Editor, Journal of Clinical Oncology 1997; 15(9): 3167–8. 26. Loprinzi CL, Ghosh C, Camoriano J, Sloan JA, Steen PD, Michalak JC, Schaefer PL,

Novotny PJ, Gerstner JB, White DF, Hatfield AK, Quella SK. Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving Fluorouracil-based chemotherapy. Journal of Clinical Oncology 1997; 15: 1235-1238.

25. Okuno S, Foote R, Loprinzi CL, Galavita S, Sloan JA, Earle J, Novotny P, Burk M,

Frank A. A Randomized Trial of a Nonabsorbable Antibiotic Lozenge for Alleviate of Radiation-Induced Mucositis. Cancer 1997; 79: 2193-2199.

24. Perez EA, Loprinzi CL, Sloan JA, Owens DT, Novotny PJ, Bonner JA. Utility of

screening procedures for detecting recurrence of disease after complete response in patients with small cell lung carcinoma. Cancer 1997; 80(4): 676–80.

23. Sloan JA, Novotny P, Loprinzi CL, Nair S. Graphical and Analytical Tools for the

analysis Two-Period Crossover Clinical Trials. SUGI proceedings 1997; 22:1312-1317. (best paper award)

22. Beaver K, Luker KA, Owens RG, Leinster SJ, Degner LF, Sloan JA. Treatment

decision making in women newly diagnosed with breast cancer. Cancer Nursing 1996; 19(1): 8–19.

21. Kristjanson LJ, Sloan JA, Dudgeon D, Adaskin E. Family members’ perceptions of

palliative cancer care: Predictors of family functioning and family members’ health. Journal of Palliative Care 1996; 12(4): 10-20.

20. Degner L, Sloan JA. Symptom distress in newly diagnosed ambulatory cancer

patients and as a predictor of survival in lung cancer. Journal of Pain and Symptom Management 1995; 10(5): 1-8.

19. Luker KA, Beaver K, Leinster S, Owens RG, Degner LF, Sloan JA. The information

needs of women newly diagnosed with breast cancer. Journal of Advanced Nursing 1995; 22: 134-141.

57

Sloan CV, 5/7/2008

18. Sloan JA, Schwarz C, Neden L. Dataset on silver-maple-tree growth regulators. Journal of the Statistical Society of Canada 1995; 23(3): 325-329.

17. Trylinski C, Sloan JA, Nemecek A. Cancer Patient trajectory through the Manitoba

17.Health care system. Journal of the National Cancer Registrars Association 1995; 21: 31-34.

16. Kraut A, Sloan JA, Silviu-Dan F, Peng Z, Gagnon D, Warrington R. Occupational

allergy after exposure to caddis flies at a hydroelectric power plant. Occupational and Environmental Medicine 1994; 51: 408-413.

15. Paterson BL, Sloan JA. A phenomenological study of decision-making experience of

individuals with long-standing diabetes. Journal of Diabetes Care 1994; 18(4): 10-19. (1995 Diabetes manuscript of the year award)

14. Sloan JA. Laypersons guide to professional titles in statistics. Chance 1994; 7:33. 13. Sloan JA. Statistical consulting is scholarship. The American Statistician 1994;

48(1): 62-63. 12. Degner, LF, Sloan, JA. Decision making during serious illness: what role do patients

really want to play? Journal Clin Epidemiol 1992; (9): 41-950. 11. Gregory, D, Russell, C , Hurd, J, Tyance, J, Sloan, J. Canada’s Indian Health

Transfer Policy: The Gull Bay Band Experience. Human Organization 1992; 51(3): 214-222.

10. Heaman M, Beaton J, Gupton A, Sloan JA. A comparison of childbirth expectations

in high risk and low risk pregnant women. Clinical Nursing Research 1992; 1(3): 252-265.

9. Schwarz C, Sloan JA, Neden L, Brewster, JF. Multiple sclerosis dataset. Journal of

the Statistical Society of Canada 1992; 20(1): 91-108. 8. Sloan JA. How to Consult with Statistician – and Live, Section on Statistical

Consulting, American Statistical Association. 9(1). Spring 1992. Chance 1998. 7. Dyck S, Brent K, Davies B, Degner L, Neufield K, Plummer H, Baker T, Stewart N,

Thomson N, Warren B, Sloan J. Development of a staging system for chemotherapy-induced stomatitis. Cancer Nursing 1991; 14(1): 6-12.

6. Gupton, A, Besaton, J, Sloan J, Bramadat, I. The development of a scale to measure

childbirth expectations. The Canadian Journal of Nursing Research 23(2):35-47, 1991.

5. Kristjanson L, Sloan JA. Evaluation of the grief experience for survivors. Journal of

Palliative Care 1991; 7(4): 51-56. 4. Sloan JA, Sinha SK. Bayesian prediction intervals for a mixture of exponential failure-

time distributions for complete and censored samples. Statistics and Probability Letters 1991; 11(6): 537-545.

3. Scruby L, Sloan JA. Evaluation of bereavement intervention. Canadian Journal of

58

Sloan CV, 5/7/2008

Public Health 1989; 80: 394-398. 2. Sinha SK, Sloan JA. Prediction interval for a mixture of Weibull failure-time

distributions - a Bayesian approach. South African Journal of Statistics 1989; 23: 119-130.

1. Sinha SK, Sloan JA. Bayes estimation of the parameters and reliability function of the

three-parameter Weibull distribution. IEEE Transactions on Reliability 1988; 37(4): 364-369.

b. Submitted to Refereed Journals (Review Pending) Hassan I, Cima RR, Sloan JA, Larson DW, Dozois EJ. Quality of life of caregivers of patients undergoing colon and rectal surgery. Caring for those who care.

c. Book Chapters, Editorials, & Technical Reports 34. Sloan JA. Statistical Issues in the Application of Cancer Outcome Measures.

Outcomes Asessment in Cancer; Measures, Methods and Applications. Edited by: Joseph Lipscomb, Carolyn C. Gotay, and Claire Snyder. Cambridge Press 2004.

33. Stockler MR, Chang VTS, Sloan JA. Design and Analysis of Controlled Trials for

Management of Pain, Depression, and Fatigue. American Society of Clinical Oncology 2004.

32. Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine reduced the frequency and

severity of hot flushes in some postmenopausal women. Evidence-based Obstetrics and Gynecology 2004; 6: 93-94.

31. Stockler MR, Chang VTS, Sloan JA. Design and Analysis of Controlled Trials for

Management of Pain, Depression, and Fatigue. Trial in Cancer Pain, Depression, and Fatigue, ASCO Educational Book 2004; 133 – 147.

30. Loprinzi CL, Sloan JA, Rowland, Jr., KM. Methodologic Issues Regarding Cancer

Anorexia/Cachexia Trials. Research and Palliative Care: Methodologies and Outcomes. Issues in Palliative Care Research edited by Russell K. Portenoy MD & Eduardo Bruera MD. Oxford Univeristy Press. 2003. pp. 25 – 40 (ISBN 0-19-513065-0)

29. Sloan J, Stewart D. Shelter Affordability and Housing Needs of Canadian Food Bank

Users, Canadian Mortgage and Housing Corporation, 1997. 28. Sloan, JA, Sinha, SK. Bayesian estimation for the bivariate normal distribution. Baye-

sian Methods in Statistics: the Zellner Volume, Donald Berry (editor), John Wiley & Sons, 1996.

27. Sloan J, Nemecek A. Experiences in Constructing Cancer Patient TrajectoriesThrough

the Manitoba Health Care System. Manitoba Cancer Treatment and Research Foundation/ Manitoba Health Organization, 1995.

26. Sloan J. Conducting Successful In-Person Interviews, Manitoba Nursing Research

Institute Technical Report #13, 1995. 25. Sloan J, Yeung A. A manual for implementing Coombs’ unidimensional unfolding

59

Sloan CV, 5/7/2008

model for paired comparisons data. Manitoba Nursing Research Institute Technical Report #12, 1994.

25. Sloan J, Doig W. A manual for carrying out Thurstone scaling analysis. Manitoba

Nursing Research Institute Technical Report #11, 1993. 23. Sloan J. Clinical trials in oncology: their design and analysis. Manitoba

NursingResearch Institute Technical Report #10, 1993. 22. Sloan J. The state of nursing research: an outsider’s perspective. Nurscene 18:9-10,

1993. 21. Sloan J, Doig W. Sample size requirements for estimating means by surveys.

Manitoba Nursing Research Institute, Technical Report #9, 1993. 20. Sloan J. Considering the research subject’s point of view: Diary of a lab rat. Nurscene

18:16-17, 1993. a. Sloan J, Doig W. Sample size requirements for estimating proportions by surveys.

Manitoba Nursing Research Institute Technical Report #8, 1993. 18. Stewart DG, Shindruk CA, Sloan J, Cavalier SE. Aging in place: a study of retirement

housing decisions of selected Winnipeg Homeowners. Housing Studies Research and Development Program, University of Manitoba, 1993.

17. Sloan J. What do nurses need to know about Statistics? Nurscene 17:4-5, 1992. 16. Adaskin E, Powell C, Beaton J, Sloan J. A survey of Manitoba baccalaureate nurses’

preferences for further study. Nurscene 17:10-11, 1992. 15. Sloan J. Survey design for health care research. Manitoba Nursing Research Institute

Technical Report #7, 1992. 14. Stewart D, Steel F, Sloan J. The economic consequences of divorce on families

owning a marital home. Ottawa: Canadian Mortgage and Housing Corporation, 1990. 13. Sloan J. Evaluation of statistical consulting for nursing research. Manitoba Nursing

Research Institute, Technical Report #6, 1990. 12. Sloan J. Assessing relative importance of nursing issues. Report of the National

Nursing Symposium, Winnipeg: Ministry of Health, 1990. 11. Sloan J. Experimental design: a question of control. MNRI Note #6, 1990. 10. Sloan J. Using the SPSS/PC+ package for nursing research: a self directed tutorial.

Manitoba Nursing Research Institute Technical Report #5, 1989. 9. Sloan J. Newspapers and research findings. MNRI Note #5, 1989. 8. Sloan J. Using the U of M mainframe for nursing research. Manitoba Nursing

Research Institute, Technical Report #4, 1988. 7. Sloan J. Stomatitis: Evidence for the effectiveness of alternative nursing interventions.

60

Sloan CV, 5/7/2008

University of Saskatchewan Nursing Research Unit Report Series, 1988. 6 Sloan J. An application of Chernoff faces to bereavement counselling. Manitoba

Technical Report #2, 1987. 5. Sloan J. Producing three dimensional plots via SAS/GRAPH with uniform axis scaling.

Manitoba Nursing Research Institute, Technical Report #3, 1987. 4. Sloan J. On the distribution and testing of Cronbach’s alpha coefficient and related

software program (CRONY). Manitoba Nursing Research Institute Technical Report #1, 1986.

3. Schwarz C, Sloan J. Interfacing the IBM PC and the AMDAHL. University of Manitoba

Department of Statistics Technical Report #158, 1985. 2. Sloan J. MULTREG: A multiple regression package for the IBM PC. International

Personal Computer Owners (IPCO) software library; Philadelphia, PA; 1983. 1. Sloan J. Probability of promotion in the Canadian Armed Forces. Department of

National Defense report, 1981.

b. Non-Refereed Publications 5. Sloan J. Searching for clinically relevant effects in QOL instruments. DIA Fifth Annual

Symposium of Contributed Papers “Quality of Life Evaluation;” Hilton Head, SC; April 5-7, 1998.

4. Sloan J. Statistician warns survey results can be misleading. Winnipeg Free Press; May

23, 1995 B2. 3. Sloan J. A layperson’s guide to opinion polls. Winnipeg Free Press; April 10, 1995. 2. Sloan J. Some suggested questions for reporters to ask of researchers, series of articles

appearing in IABC, the newsletter of the International Association of Business Communicators, 1994/1995.

1. Sloan J. Uniform scaling in presenting three-dimensional data via SAS/GRAPH. SAS

Communications 6:118-120, 1988.

61

curriculum vitae jeff a. sloan, ph.d. address office: cancer...

Documents